Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Rheumatology›Condition·Updated Jul 11, 2026·v1

Systemic Lupus Erythematosus

Systemic lupus erythematosus is a chronic autoimmune disease with heterogeneous presentation, affecting multiple organ systems. Diagnosis requires a high index of suspicion, supported by ANA testing and the 2019 EULAR/ACR classification criteria. Management centers on hydroxychloroquine as foundation therapy, treat-to-target aiming for LLDAS or DORIS remission, judicious use of glucocorticoids, and escalation to DMARDs and biologics (belimumab, anifrolumab) for moderate-to-severe disease. Aggressive management of comorbidities, infection prophylaxis, and structured monitoring are essential to reduce the three-fold excess mortality driven by cardiovascular disease, infection, and renal failure.

High Evidence566 references·9,976 words·40 min read·v1
SLEsystemic lupus erythematosusautoimmune diseaserheumatologylupus nephritisantiphospholipid syndromehydroxychloroquinebelimumabanifrolumabtreat-to-target

Quick Reference

RxDrug of choiceHydroxychloroquine ≤5 mg/kg/day (max 400 mg) for all patients; add belimumab 10 mg/kg IV every 4 weeks or anifrolumab 300 mg IV every 4 weeks for moderate-to-severe disease. For lupus nephritis: mycophenolate mofetil 2-3 g/day or low-dose IV cyclophosphamide plus corticosteroids, with add-on belimumab or voclosporin.
AltAlternativesMethotrexate 15-25 mg weekly for non-renal disease; azathioprine 1-2.5 mg/kg/day; mycophenolate mofetil 1-3 g/day; obinutuzumab 1000 mg IV for refractory non-renal SLE; rituximab 1 g IV × 2 for organ-threatening disease; voclosporin 23.7 mg twice daily for lupus nephritis.
⊘AvoidMycophenolate and methotrexate in pregnancy; cyclophosphamide in active infection; TNF inhibitors (ineffective); non-dihydropyridine CCBs in heart failure; live vaccines during high-dose immunosuppression.
DxTest of choiceANA by indirect immunofluorescence on HEp-2 cells (screening); anti-dsDNA and anti-Sm for specificity; complement C3/C4 for disease activity; renal biopsy for suspected lupus nephritis.
ScKey score2019 EULAR/ACR classification criteria (score ≥10); SLEDAI-2K for disease activity; LLDAS and DORIS for treat-to-target; SDI for damage.
→When to referRheumatology for all SLE patients; nephrology for renal biopsy and LN management; neurology for NPSLE; maternal-fetal medicine for pregnancy; ophthalmology for HCQ retinopathy screening.
Initiate hydroxychloroquine in all patients, treat to target (LLDAS or DORIS), minimize glucocorticoids, add biologics (belimumab/anifrolumab) for moderate-to-severe disease, and manage comorbidities aggressively to reduce damage accrual and mortality.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement, driven by loss of self-tolerance, type I interferon signaling, and immune complex deposition. It affects approximately 3.41 million people globally, with a 9:1 female predominance and highest prevalence in Black women (230.9 per 100,000) and American Indian/Alaska Native populations. All-cause mortality is three-fold higher than the general population, primarily from cardiovascular disease, infection, and renal failure. Early diagnosis using the 2019 EULAR/ACR classification criteria, treat-to-target strategies aiming for Lupus Low Disease Activity State (LLDAS) or DORIS remission, and aggressive management of comorbidities are essential to reduce damage accrual and improve outcomes.

Overview and Recommendations

Background

  • •SLE is a chronic autoimmune disease characterized by loss of self-tolerance, production of autoantibodies to nuclear antigens, immune complex deposition, and inflammation of multiple organ systems. It affects approximately 3.41 million people globally, with a prevalence of 72.8 per 100,000 in the United States and a striking 9:1 female-to-male ratio. Black women have the highest prevalence (230.9 per 100,000), followed by Hispanic (120.7) and White (84.7) women; American Indian/Alaska Native women reach 270.6 per 100,000.
  • •All-cause mortality is three-fold higher than the general population (meta-SMR 2.98), driven by cardiovascular disease, infection, and renal disease. The immunopathogenesis involves a core loop: defective clearance of apoptotic debris and neutrophil extracellular traps (NETs) exposes self-nucleic acids, triggering type I interferon (IFN-I) production, B-cell hyperactivity, and autoantibody formation that propagate immune complex deposition and tissue injury.
  • •Three clinical phenotypes identified by cluster analysis of the 2019 EULAR/ACR criteria: mucocutaneous/articular (Cluster 1, best prognosis), severe renal (Cluster 2, worst prognosis with high anti-dsDNA and anti-Sm, highest damage accrual), and mixed connective tissue disease overlap (Cluster 3, anti-U1-RNP positive, intermediate outcome).
  • •Classification of SLE uses the 2019 EULAR/ACR criteria, which require a positive antinuclear antibody (ANA) at ≥1:80 titer as an entry criterion, followed by weighted additive criteria in seven clinical and three immunologic domains. A score of ≥10 classifies SLE with sensitivity 96.1% and specificity 93.4%, outperforming earlier ACR 1997 and SLICC 2012 criteria.
  • •Key clinical variants include lupus nephritis (30-50% of patients, especially proliferative classes III/IV), neuropsychiatric SLE (20-40% cumulative incidence, ranging from headache to psychosis and transverse myelitis), antiphospholipid syndrome (30-40%, with thrombosis and pregnancy loss), serositis (10-20%), and hematologic predominant disease (50-70% with any cytopenia).

Evaluation

  • •Suspect SLE in any patient, especially women of childbearing age, presenting with unexplained fatigue, malar rash (fixed erythema sparing nasolabial folds), painless oral ulcers, non-scarring alopecia, or symmetric non-erosive polyarthritis of small joints. The presence of any two of these three signs, malar rash, oral ulcers, alopecia, has a likelihood ratio >10 for SLE in patients with undiagnosed multisystem symptoms.
  • •Ask about constitutional symptoms (fever, weight loss, fatigue), photosensitivity, Raynaud's phenomenon, pleuritic chest pain, pericardial rub, seizures, psychosis, cognitive dysfunction, history of venous or arterial thrombosis, recurrent pregnancy loss, and prior depressive disorder (which increases SLE risk 2.3-fold).
  • •Examine for malar/discoid rash, oral/nasal ulcers, alopecia, synovitis, serositis (pleural or pericardial rub), lymphadenopathy, hepatosplenomegaly, and neurologic deficits. Document blood pressure and check for peripheral edema suggesting renal involvement.
  • •Order ANA by indirect immunofluorescence on HEp-2 cells as the first test. A negative ANA at 1:80 dilution effectively rules out SLE (sensitivity >95%). If positive, proceed with autoantibody panel: anti-dsDNA (ELISA or Crithidia luciliae), anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-RNP, and antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I). Also check complement C3/C4, complete blood count, urinalysis with protein-to-creatinine ratio, and serum creatinine.
  • •Apply the 2019 EULAR/ACR classification criteria: ANA positive entry criterion, then assign weighted scores in clinical domains (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and immunologic domains (antiphospholipid antibodies, complement, SLE-specific antibodies). A cumulative score of ≥10 classifies SLE. Key weighted items: malar rash (6 points), discoid rash (4), oral ulcers (2), non-scarring alopecia (2), synovitis (6), pleural or pericardial effusion (5), proteinuria >0.5 g/24h (4), renal biopsy class III/IV (10), seizures (5), psychosis (3), hemolytic anemia (4), leukopenia (3), thrombocytopenia (4), anti-dsDNA (6), anti-Sm (6), antiphospholipid antibodies (2 points each), low complement (3).
  • •Diagnostic criteria are clinical; the classification criteria support diagnosis but are not formal diagnostic criteria. However, they provide a robust framework for identifying SLE, especially when combined with typical clinical features and serology.
  • •For suspected lupus nephritis, obtain a renal biopsy for ISN/RPS classification (class III/IV proliferative, class V membranous, or mixed). Biopsy is essential to guide treatment decisions and predict prognosis. For neuropsychiatric symptoms, perform MRI, CSF analysis, and EEG to exclude infection, stroke, or other causes. Joint ultrasound or MRI can document synovitis fulfilling the musculoskeletal domain.
  • •Consider differential diagnoses: drug-induced lupus (typically with anti-histone antibodies), rheumatoid arthritis, Sjögren disease, systemic sclerosis, mixed connective tissue disease, infection (e.g., parvovirus B19, HIV, EBV, leprosy), and malignancy. Arthrocentesis is indicated to exclude septic arthritis or crystal arthropathy in patients with arthritis; SLE synovial fluid is inflammatory with mononuclear predominance.

Management

  • •Initiate hydroxychloroquine (HCQ) at ≤5 mg/kg real body weight/day (maximum 400 mg/day) for every patient with SLE unless contraindicated. HCQ reduces flare risk, improves lipid profiles, and confers a survival benefit. Do not withdraw HCQ unless retinal toxicity occurs; withdrawal increases flare risk 2.5-fold.
  • •For mild-to-moderate non-renal disease inadequately controlled by HCQ, add a conventional synthetic DMARD: methotrexate 15-25 mg once weekly (first-line for arthritis and rash), azathioprine 1-2.5 mg/kg/day, or mycophenolate mofetil 1-3 g/day. Use folic acid with methotrexate.
  • •For moderate-to-severe non-renal disease despite HCQ and csDMARDs, add a biologic: belimumab IV 10 mg/kg every 4 weeks or SC 200 mg weekly, or anifrolumab IV 300 mg every 4 weeks. Both are first-line add-on biologics per EULAR 2023. Belimumab reduces severe flare risk by 50% (HR 0.51); anifrolumab improves BICLA response (47.8% vs 31.5%).
  • •For lupus nephritis (class III/IV ± V), induce with mycophenolate mofetil 2-3 g/day OR low-dose IV cyclophosphamide 500 mg/m² every 2 weeks for 6 doses, combined with IV methylprednisolone 0.5-1 g/day for 3 days, then oral prednisone 0.5-1 mg/kg/day tapered to ≤7.5 mg/day by 3 months. Add belimumab 10 mg/kg IV every 4 weeks or voclosporin 23.7 mg twice daily for improved renal response (complete renal response at 1 year: 41% vs 23% with voclosporin).
  • •For severe neuropsychiatric SLE (e.g., transverse myelitis, vasculitis, psychosis), give high-dose IV methylprednisolone 1 g/day for 3-5 days plus IV cyclophosphamide 500-1000 mg/m² monthly for 6 months. Consider rituximab 1 g IV × 2 doses 2 weeks apart if refractory.
  • •For severe thrombocytopenia (<30,000/μL) or autoimmune hemolytic anemia (Hb <8 g/dL), administer IV methylprednisolone 1 g/day for 3 days, IVIG 0.4 g/kg/day for 5 days, ± rituximab. Avoid splenectomy if possible as it may increase infection risk.
  • •For refractory disease, escalate therapy: switch between MMF and cyclophosphamide, or add obinutuzumab 1000 mg IV on day 1 and week 2, then every 24 weeks (SRI-4 response 76.7% vs 53.5% in non-renal SLE). Rituximab remains a rescue option for organ-threatening disease but carries a higher serious infection rate (117.7 per 1000 person-years).
  • •Monitor disease activity every 1-3 months with CBC, creatinine, urinalysis, complement C3/C4, and anti-dsDNA. For lupus nephritis, monitor 24-hour urine protein and eGFR weekly during induction, then monthly. Document the Lupus Low Disease Activity State (LLDAS) components: SLEDAI-2K ≤4, no major organ activity, PGA ≤1, prednisone ≤7.5 mg/day, and stable immunosuppressants.
  • •Taper glucocorticoids aggressively: aim for prednisone ≤5 mg/day by 3-6 months, then withdrawal. Prolonged exposure >7.5 mg/day increases damage accrual, cataracts, osteoporosis, and osteonecrosis. Every 1 mg/day reduction below 7.5 mg improves long-term outcomes.
  • •Provide infection prophylaxis: give trimethoprim-sulfamethoxazole 80/400 mg daily for Pneumocystis jirovecii if prednisone >20 mg/day for >4 weeks or with cyclophosphamide. Administer recombinant zoster vaccine (RZV) before starting biologics if possible. Screen for latent TB, hepatitis B, hepatitis C, and HIV before initiating biologics. For patients on rituximab, monitor IgG levels and consider IVIG 0.4 g/kg every 4 weeks if IgG <500 mg/dL and recurrent serious infections.
  • •What NOT to do: avoid mycophenolate mofetil in pregnancy (teratogenic); avoid cyclophosphamide in active infection without adequate antimicrobial coverage; avoid abrupt steroid withdrawal; avoid TNF inhibitors (ineffective in SLE and may induce autoantibodies); avoid non-dihydropyridine CCBs (diltiazem, verapamil) in patients with heart failure or lupus nephritis.
  • •When to refer: to rheumatology for all SLE patients; to nephrology for renal biopsy and management of lupus nephritis; to neurologist for neuropsychiatric SLE; to maternal-fetal medicine for pregnancy in SLE; to ophthalmology for baseline and annual retinopathy screening after 5 years of HCQ use.
  • •Treat-to-target: aim for DORIS remission (clinical SLEDAI-2K = 0, PGA <0.5, prednisone ≤5 mg/day, stable immunosuppressants) or LLDAS. Sustained target for ≥3 consecutive months reduces damage accrual by 40% (HR 0.60) and flare by 44% (HR 0.56). Achieving LLDAS for ≥50% of observed time cuts mortality risk by nearly half (adjusted HR 0.51).
  • •Discharge criteria for hospitalized flares: clinical improvement of organ-threatening manifestations, stable vital signs, ability to taper steroids, and follow-up arranged within 2 weeks. For acute flares, initiate high-dose glucocorticoids and appropriate immunosuppressive therapy within 24 hours to prevent irreversible organ damage.

Board Review — High Yield

  • •Malar rash, Fixed erythema over malar eminences, sparing nasolabial folds; most specific mucocutaneous sign.
  • •Anti-dsDNA, Highly specific for SLE, correlates with disease activity and lupus nephritis; weighted 6 points in EULAR/ACR criteria.
  • •Anti-Sm, Pathognomonic for SLE, stable over time; weighted 6 points; sensitivity 20-30% but >99% specificity.
  • •Lupus nephritis Class III/IV, Proliferative LN requires aggressive induction with MMF or cyclophosphamide plus corticosteroids; add belimumab or voclosporin.
  • •LLDAS, Lupus Low Disease Activity State: SLEDAI-2K ≤4, no major organ activity, PGA ≤1, prednisone ≤7.5 mg/day, stable immunosuppressants; reduces damage accrual by 40%.
  • •Hydroxychloroquine retinopathy, Dose-dependent risk; keep ≤5 mg/kg/day; annual screening after 5 years with Humphrey 10-2 visual fields and SD-OCT.
  • •Anifrolumab, Type I IFN receptor antagonist; improves BICLA response in moderate-to-severe SLE; increases herpes zoster risk (OR 3.45).
  • •Catastrophic APS, Rapid multiorgan failure with microthrombosis; treat with anticoagulation, high-dose glucocorticoids, plasmapheresis, ± rituximab, ± eculizumab.
  • •Pregnancy in SLE, Continue HCQ; avoid MMF, MTX, CYC; monitor for congenital heart block if anti-Ro positive; low-dose aspirin plus heparin for APS.

Deep Dive — Evidence Details

References

  1. [1]

    Aringer M, Costenbader K, Daikh D et al.. “2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.” Annals of the rheumatic diseases (2019). PMID: 31383717 ↗

    L1GUIDELINECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  2. [2]

    Morand EF, van Vollenhoven R, Furie RA et al.. “LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials.” Annals of the rheumatic diseases (2025). PMID: 39948001 ↗

    L2RCTCited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  3. [3]

    Agmon-Levin N, Ignatenko S, Gordienko A et al.. “B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment.” Annals of the rheumatic diseases (2025). PMID: 41353079 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease
  4. [4]

    Olsen NJ, Liao D, James JA et al.. “A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40955637 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  5. [5]

    Hu Z, Cai S, Yu Y et al.. “BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis.” Annals of the rheumatic diseases (2025). PMID: 40681435 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  6. [6]

    Morand EF, Abreu G, Furie RA et al.. “Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.” Annals of the rheumatic diseases (2023). PMID: 36690388 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Long-term Management: The DMARD Ladder & Treat-to-Target
  7. [7]

    Izmirly PM, Parton H, Wang L et al.. “Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33474834 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prevention, Screening & Surveillance
  8. [8]

    Lai ZW, Kelly R, Winans T et al.. “Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.” Lancet (London, England) (2018). PMID: 29551338 ↗

    L4RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  9. [9]

    Luo C, Su S, Liu J et al.. “Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 41147706 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease
  10. [10]

    Papazoglou N, Sfikakis PP, Tektonidou MG. “Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10-Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39721769 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  11. [11]

    Yurkovich M, Vostretsova K, Chen W et al.. “Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.” Arthritis care & research (2014). PMID: 24106157 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Complications: Disease-Driven & Treatment-Related
  12. [12]

    Leuchten N, Hoyer A, Brinks R et al.. “Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data.” Arthritis care & research (2018). PMID: 28544593 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  13. [13]

    Yang Z, Cheng C, Wang Z et al.. “Prevalence, Predictors, and Prognostic Benefits of Remission Achievement in Patients With Systemic Lupus Erythematosus: A Systematic Review.” Arthritis care & research (2022). PMID: 32986933 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  14. [14]

    Kandane-Rathnayake R, Golder V, Louthrenoo W et al.. “Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.” The Lancet. Rheumatology (2022). PMID: 38261390 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  15. [15]

    Parodis I, Lindblom J, Tsoi A et al.. “Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab.” Rheumatology (Oxford, England) (2025). PMID: 39412507 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  16. [16]

    Bortoluzzi A, Fanouriakis A, Silvagni E et al.. “Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study.” Rheumatology (Oxford, England) (2024). PMID: 38402539 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  17. [17]

    Fanouriakis A, Tziolos N, Bertsias G et al.. “Update οn the diagnosis and management of systemic lupus erythematosus.” Annals of the rheumatic diseases (2020). PMID: 33051219 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  18. [18]

    Franklyn K, Lau CS, Navarra SV et al.. “Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).” Annals of the rheumatic diseases (2015). PMID: 26458737 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  19. [19]

    Aringer M, Costenbader K, Daikh D et al.. “2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 31385462 ↗

    L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  20. [20]

    Carlomagno R, Gold N, Liao F et al.. “Genetics of Childhood-Onset Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40356234 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  21. [21]

    Fava A, Wagner CA, Guthridge CJ et al.. “Association of Autoantibody Concentrations and Trajectories With Lupus Nephritis Histologic Features and Treatment Response.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38962936 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  22. [22]

    Müller F, Taubmann J, Bucci L et al.. “CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.” The New England journal of medicine (2024). PMID: 38381673 ↗

    L4CASE_REPORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  23. [23]

    Moe SR, Haukeland H, Brunborg C et al.. “Accrual of thromboembolic events and antiphospholipid syndrome in new-onset systemic lupus erythematosus: a population-based inception cohort study.” RMD open (2025). PMID: 40903053 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
  24. [24]

    Guedon AF, Ricard L, Laurent C et al.. “Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study.” RMD open (2023). PMID: 36894193 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  25. [25]

    Fierro JJ, Prins JR, Verstappen GM et al.. “Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sjögren's syndrome: a retrospective cohort study.” RMD open (2023). PMID: 37652559 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Special Populations, Pregnancy & Fertility
  26. [26]

    Silva CA, Avcin T, Brunner HI. “Taxonomy for systemic lupus erythematosus with onset before adulthood.” Arthritis care & research (2012). PMID: 22730317 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Special Populations, Pregnancy & Fertility
  27. [27]

    Tedeschi SK, Johnson SR, Boumpas D et al.. “Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.” Arthritis care & research (2018). PMID: 28692774 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  28. [28]

    Valenzuela-Almada MO, Hocaoglu M, Dabit JY et al.. “Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study.” Arthritis care & research (2022). PMID: 34825516 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  29. [29]

    Case SM, Feldman CH, Guan H et al.. “Posttraumatic Stress Disorder and Risk of Systemic Lupus Erythematosus Among Medicaid Recipients.” Arthritis care & research (2022). PMID: 34309239 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  30. [30]

    Tani C, Cardelli C, Moroni L et al.. “Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study.” The Lancet. Rheumatology (2026). PMID: 41655581 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  31. [31]

    Bolla E, Semb AG, Petri M et al.. “Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries.” The Lancet. Rheumatology (2025). PMID: 41274305 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
  32. [32]

    Hoi A, Igel T, Mok CC et al.. “Systemic lupus erythematosus.” Lancet (London, England) (2024). PMID: 38642569 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  33. [33]

    Dörner T, Furie R. “Novel paradigms in systemic lupus erythematosus.” Lancet (London, England) (2019). PMID: 31180031 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  34. [34]

    Lisnevskaia L, Murphy G, Isenberg D. “Systemic lupus erythematosus.” Lancet (London, England) (2014). PMID: 24881804 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
  35. [35]

    Durcan L, O'Dwyer T, Petri M. “Management strategies and future directions for systemic lupus erythematosus in adults.” Lancet (London, England) (2019). PMID: 31180030 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  36. [36]

    Goldblatt F, O'Neill SG. “Clinical aspects of autoimmune rheumatic diseases.” Lancet (London, England) (2013). PMID: 23993190 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  37. [37]

    Lin A, Kandane-Rathnayake R, Morand EF et al.. “Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.” Lupus science & medicine (2026). PMID: 42167880 ↗

    L2RCTCited in: Definition, Classification & Nomenclature, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  38. [38]

    Doria A, van Vollenhoven RF, Morand EF et al.. “Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trials.” Lupus science & medicine (2026). PMID: 41951251 ↗

    L2RCTCited in: Definition, Classification & Nomenclature
  39. [39]

    Parodis I, Lindblom J, Levy RA et al.. “Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.” RMD open (2026). PMID: 42399079 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  40. [40]

    Shan L, Wang Z, Li S et al.. “Autologous CD19 CAR-T cell therapy for pediatric and adult systemic lupus erythematosus: A phase 1/2 trial.” Molecular therapy : the journal of the American Society of Gene Therapy (2026). PMID: 41935952 ↗

    L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
  41. [41]

    Hannon CW, McCourt C, Lima HC et al.. “Interventions for cutaneous disease in systemic lupus erythematosus.” The Cochrane database of systematic reviews (2021). PMID: 33687069 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  42. [42]

    Fernandes Moça Trevisani V, Castro AA, Ferreira Neves Neto J et al.. “Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.” The Cochrane database of systematic reviews (2013). PMID: 23450535 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  43. [43]

    García-Sáenz MR, Ramírez-Rentería C, Espinosa-Cárdenas E et al.. “Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42290873 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Special Populations, Pregnancy & Fertility
  44. [44]

    Yu C, Hui J, Ding S et al.. “Global prevalence, site-specific patterns, and key risk factors for osteoporosis and bone loss in systemic lupus erythematosus: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42064088 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  45. [45]

    Aringer M, Johnson SR. “Classifying and diagnosing systemic lupus erythematosus in the 21st century.” Rheumatology (Oxford, England) (2020). PMID: 33280013 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  46. [46]

    Thong B, Olsen NJ. “Systemic lupus erythematosus diagnosis and management.” Rheumatology (Oxford, England) (2017). PMID: 28013206 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  47. [47]

    Liao K, Li N, Bonin J et al.. “The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus.” Rheumatology (Oxford, England) (2025). PMID: 39141489 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  48. [48]

    Zayat AS, Mahmoud K, Md Yusof MY et al.. “Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus.” Rheumatology (Oxford, England) (2019). PMID: 30265343 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Long-term Management: The DMARD Ladder & Treat-to-Target
  49. [49]

    Tay SH, Mak A. “Diagnosing and attributing neuropsychiatric events to systemic lupus erythematosus: time to untie the Gordian knot?” Rheumatology (Oxford, England) (2017). PMID: 27744358 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  50. [50]

    Beydon M, McCoy S, Nguyen Y et al.. “Epidemiology of Sjögren syndrome.” Nature reviews. Rheumatology (2023). PMID: 38110617 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  51. [51]

    Bossuyt X, De Langhe E, Borghi MO et al.. “Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases.” Nature reviews. Rheumatology (2020). PMID: 33154583 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  52. [52]

    Goldbach-Mansky R, Alehashemi S, de Jesus AA. “Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus.” Nature reviews. Rheumatology (2024). PMID: 39623155 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  53. [53]

    Cutolo M, Soldano S, Smith V et al.. “Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases.” Nature reviews. Rheumatology (2025). PMID: 40721670 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  54. [54]

    Carter EE, Barr SG, Clarke AE. “The global burden of SLE: prevalence, health disparities and socioeconomic impact.” Nature reviews. Rheumatology (2016). PMID: 27558659 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  55. [55]

    Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. “Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.” Nature reviews. Rheumatology (2022). PMID: 35039665 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  56. [56]

    Marshall L, Raychaudhuri S, Viatte S. “Understanding rheumatic disease through continuous cell state analysis.” Nature reviews. Rheumatology (2025). PMID: 40335652 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  57. [57]

    Zolio L, Hao Y, Kandane-Rathnayake R et al.. “Predictive correlates of arthritis and joint damage in systemic lupus erythematosus: a multinational prospective cohort study.” Rheumatology (Oxford, England) (2026). PMID: 42114134 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  58. [58]

    Le Tallec E, Bourg C, Bouzillé G et al.. “Prognostic insights from symptom clustering analysis in systemic lupus erythematosus.” RMD open (2025). PMID: 40210260 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  59. [59]

    Garantziotis P, Nikolopoulos D, Katechis S et al.. “Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage.” RMD open (2025). PMID: 41033712 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  60. [60]

    Michelakis IE, Panagiotopoulos A, Kapsia E et al.. “Predictors of a successful glucocorticoid tapering and withdrawal in an inception cohort of patients with lupus nephritis and associations with long-term outcomes and damage accrual.” RMD open (2025). PMID: 41120201 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  61. [61]

    Fujita Y, Nakayamada S, Kubo S et al.. “Association of peripheral CD8+ T cell activation with disease activity and treatment resistance in systemic lupus erythematosus.” RMD open (2025). PMID: 40010940 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  62. [62]

    Andreoli L, Bertsias GK, Agmon-Levin N et al.. “EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.” Annals of the rheumatic diseases (2016). PMID: 27457513 ↗

    L1GUIDELINECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  63. [63]

    Furie R, Werth VP, Milliman E et al.. “Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40488251 ↗

    L1RCTCited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target
  64. [64]

    Akizuki S, Ishigaki K, Kochi Y et al.. “PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes.” Annals of the rheumatic diseases (2019). PMID: 30679154 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism
  65. [65]

    Santosa A, Tan TC. “CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic review of clinical outcomes and safety profiles.” RMD open (2026). PMID: 41781158 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism
  66. [66]

    Crow MK. “Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets.” Annals of the rheumatic diseases (2023). PMID: 36792346 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  67. [67]

    Schett G, Nagy G, Krönke G et al.. “B-cell depletion in autoimmune diseases.” Annals of the rheumatic diseases (2024). PMID: 38777374 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  68. [68]

    Agmon-Levin N, Damoiseaux J, Kallenberg C et al.. “International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.” Annals of the rheumatic diseases (2013). PMID: 24126457 ↗

    L1OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  69. [69]

    Liu Y, Zhang Z, Kang Z et al.. “Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus.” Annals of the rheumatic diseases (2023). PMID: 37567607 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  70. [70]

    Leffler J, Bengtsson AA, Blom AM. “The complement system in systemic lupus erythematosus: an update.” Annals of the rheumatic diseases (2014). PMID: 24845390 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  71. [71]

    Pisetsky DS, Herbert A. “The role of DNA in the pathogenesis of SLE: DNA as a molecular chameleon.” Annals of the rheumatic diseases (2024). PMID: 38749573 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  72. [72]

    Frangou E, Chrysanthopoulou A, Mitsios A et al.. “REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A).” Annals of the rheumatic diseases (2018). PMID: 30563869 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  73. [73]

    Nigrovic PA. “Macrophage Activation Syndrome.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39491365 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related
  74. [74]

    Taubmann J, Müller F, Yalcin Mutlu M et al.. “CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38114423 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  75. [75]

    Montano EN, Bose M, Huo L et al.. “α-Ketoglutarate-Dependent KDM6 Histone Demethylases and Interferon-Stimulated Gene Expression in Lupus.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37800478 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  76. [76]

    Tay SH, Celhar T, Fairhurst AM. “Low-Density Neutrophils in Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32524751 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  77. [77]

    Crow MK, Olferiev M, Kirou KA. “Standing on Shoulders: Interferon Research From Viral Interference to Lupus Pathogenesis and Treatment.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38500017 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  78. [78]

    Kello N, Anderson E, Diamond B. “Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 31102496 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  79. [79]

    MacLauchlan S, Fitzgerald KA, Gravallese EM. “Intracellular Sensing of DNA in Autoinflammation and Autoimmunity.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35656967 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  80. [80]

    Hanly JG, Kozora E, Beyea SD et al.. “Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29927108 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  81. [81]

    Lungova K, Putman M. “Barriers to CAR T-cell therapy in rheumatology.” The Lancet. Rheumatology (2024). PMID: 39515366 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related
  82. [82]

    Carter LM, Ehrenstein MR, Vital EM. “Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.” The Lancet. Rheumatology (2025). PMID: 40058377 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, History and Evolution of Treatment
  83. [83]

    Yaung KN, Yeo JG, Kumar P et al.. “Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus.” The Lancet. Rheumatology (2023). PMID: 38251610 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  84. [84]

    Schett G, Mackensen A, Mougiakakos D. “CAR T-cell therapy in autoimmune diseases.” Lancet (London, England) (2023). PMID: 37748491 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  85. [85]

    Steri M, Orrù V, Idda ML et al.. “Overexpression of the Cytokine BAFF and Autoimmunity Risk.” The New England journal of medicine (2017). PMID: 28445677 ↗

    L3OTHERCited in: Pathophysiology & Mechanism, Clinical Presentation
  86. [86]

    Singh JA, Shah NP, Mudano AS. “Belimumab for systemic lupus erythematosus.” The Cochrane database of systematic reviews (2021). PMID: 33631841 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  87. [87]

    Constantin AM, Mărginean N, Constantinescu AM et al.. “Altered reproductive hormone profiles in systemic lupus erythematosus - A systematic review and meta-analysis.” Autoimmunity reviews (2026). PMID: 42409298 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease
  88. [88]

    Liu H, Yu H, Lü J et al.. “Dual BAFF/APRIL inhibition with telitacicept in systemic lupus erythematosus and IgA nephropathy: pharmacological rationale, clinical efficacy, and safety on female fertility preservation.” Frontiers in pharmacology (2026). PMID: 42244869 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism, Special Populations, Pregnancy & Fertility
  89. [89]

    González García A, Fernández-Martín J, Robles Marhuenda Á. “Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.” Rheumatology (Oxford, England) (2023). PMID: 35997567 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  90. [90]

    Arriens C, Wren JD, Munroe ME et al.. “Systemic lupus erythematosus biomarkers: the challenging quest.” Rheumatology (Oxford, England) (2017). PMID: 28013203 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  91. [91]

    Davis LS, Reimold AM. “Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.” Rheumatology (Oxford, England) (2017). PMID: 28375452 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target
  92. [92]

    Kremer Hovinga IC, Koopmans M, de Heer E et al.. “Chimerism in systemic lupus erythematosus--three hypotheses.” Rheumatology (Oxford, England) (2006). PMID: 17135226 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  93. [93]

    Celhar T, Fairhurst AM. “Modelling clinical systemic lupus erythematosus: similarities, differences and success stories.” Rheumatology (Oxford, England) (2017). PMID: 28013204 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  94. [94]

    Zharkova O, Celhar T, Cravens PD et al.. “Pathways leading to an immunological disease: systemic lupus erythematosus.” Rheumatology (Oxford, England) (2017). PMID: 28375453 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  95. [95]

    Lauwerys BR, Ducreux J, Houssiau FA. “Type I interferon blockade in systemic lupus erythematosus: where do we stand?” Rheumatology (Oxford, England) (2013). PMID: 24344319 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  96. [96]

    Gensous N, Schmitt N, Richez C et al.. “T follicular helper cells, interleukin-21 and systemic lupus erythematosus.” Rheumatology (Oxford, England) (2017). PMID: 27498357 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  97. [97]

    Karim MY, Pisoni CN, Khamashta MA. “Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!” Rheumatology (Oxford, England) (2009). PMID: 19155279 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  98. [98]

    Lichtnekert J, Anders HJ. “Lupus nephritis-related chronic kidney disease.” Nature reviews. Rheumatology (2024). PMID: 39317803 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  99. [99]

    Patiño-Martinez E, Kaplan MJ. “Immunometabolism in systemic lupus erythematosus.” Nature reviews. Rheumatology (2025). PMID: 40524030 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  100. [100]

    Legge AC, Hanly JG. “Recent advances in the diagnosis and management of neuropsychiatric lupus.” Nature reviews. Rheumatology (2024). PMID: 39358609 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  101. [101]

    Szekanecz Z, McInnes IB, Schett G et al.. “Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.” Nature reviews. Rheumatology (2021). PMID: 34341562 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  102. [102]

    Schrezenmeier E, Dörner T. “Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.” Nature reviews. Rheumatology (2020). PMID: 32034323 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  103. [103]

    Tsokos GC, Lo MS, Costa Reis P et al.. “New insights into the immunopathogenesis of systemic lupus erythematosus.” Nature reviews. Rheumatology (2016). PMID: 27872476 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target
  104. [104]

    Schwartz N, Stock AD, Putterman C. “Neuropsychiatric lupus: new mechanistic insights and future treatment directions.” Nature reviews. Rheumatology (2019). PMID: 30659245 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  105. [105]

    Klein B, Billi AC, Abernathy-Close L et al.. “Cutaneous lupus erythematosus - from pathogenesis to targeted therapy.” Nature reviews. Rheumatology (2025). PMID: 41204012 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prevention, Screening & Surveillance
  106. [106]

    Tanaka Y, Luo Y, O'Shea JJ et al.. “Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.” Nature reviews. Rheumatology (2022). PMID: 34987201 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  107. [107]

    Vilas-Boas A, Morais SA, Isenberg DA. “Belimumab in systemic lupus erythematosus.” RMD open (2015). PMID: 26509047 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  108. [108]

    Satoh-Kanda Y, Nakayamada S, Tanaka Y. “Fine-tuning SLE treatment: the potential of selective TYK2 inhibition.” RMD open (2024). PMID: 39740929 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  109. [109]

    Blache U, Tretbar S, Koehl U et al.. “CAR T cells for treating autoimmune diseases.” RMD open (2023). PMID: 37996128 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  110. [110]

    Claßen P, Meineck M, Plath M et al.. “Treatment with caspase-1 inhibitor diminishes kidney disease in MRL-Faslpr mice and delays systemic illness.” RMD open (2025). PMID: 41436137 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  111. [111]

    Dörner T, Szelinski F, Lino AC et al.. “Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus.” RMD open (2020). PMID: 32675278 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target
  112. [112]

    Flint SM, Jovanovic V, Teo BW et al.. “Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases.” RMD open (2016). PMID: 27252891 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  113. [113]

    Dey M, Dey M. “PARP1 as a novel therapeutic and diagnostic tool in autoimmune rheumatic diseases: a systematic literature review.” Rheumatology international (2026). PMID: 42262597 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism
  114. [114]

    van Vliet LC, Dorjée AL, van der Heide M et al.. “Symmetrical dimethylarginine as the central antigenic determinant of anti-Smith autoantibodies in systemic lupus erythematosus.” Annals of the rheumatic diseases (2026). PMID: 42431785 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  115. [115]

    Jones E, Cano-Gamez K. “The emerging clinical relevance of cell-free DNA in lupus: from mechanistic insights to therapeutic opportunities.” Frontiers in immunology (2026). PMID: 42416073 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  116. [116]

    Scindia Y, Morel L. “Metabolic determinants of autoimmune kidney diseases.” Nature reviews. Nephrology (2026). PMID: 42410158 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  117. [117]

    Bruschi M, Alberici F, Moroni G et al.. “The landscape of serum autoantibodies in lupus nephritis.” Autoimmunity reviews (2026). PMID: 42409299 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  118. [118]

    Li Q, Zhang W, Chen Y et al.. “Accelerated immunosenescence in SLE: current evidence and clinical translation.” Frontiers in immunology (2026). PMID: 42389515 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  119. [119]

    Feng A, Li Q, Jiang N et al.. “The Dual Roles of Regulatory B Cells in Infection, Cancer, and Immunity.” MedComm (2026). PMID: 42368777 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  120. [120]

    Bertsias GK, Ioannidis JP, Aringer M et al.. “EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.” Annals of the rheumatic diseases (2010). PMID: 20724309 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  121. [121]

    Wu D, Li J, Xu D et al.. “Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.” Annals of the rheumatic diseases (2024). PMID: 38129117 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, History and Evolution of Treatment, Prognosis & Natural History
  122. [122]

    Zhang F, Bae SC, Bass D et al.. “A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.” Annals of the rheumatic diseases (2018). PMID: 29295825 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  123. [123]

    Kalunian KC, Furie R, Morand EF et al.. “A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36369793 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
  124. [124]

    Furie R, Khamashta M, Merrill JT et al.. “Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28130918 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  125. [125]

    Stohl W, Schwarting A, Okada M et al.. “Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28118533 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  126. [126]

    Tian J, Zhang D, Yao X et al.. “Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.” Annals of the rheumatic diseases (2022). PMID: 36241363 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  127. [127]

    Wang YF, Wei W, Tangtanatakul P et al.. “Identification of Shared and Asian-Specific Loci for Systemic Lupus Erythematosus and Evidence for Roles of Type III Interferon Signaling and Lysosomal Function in the Disease: A Multi-Ancestral Genome-Wide Association Study.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 34783190 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  128. [128]

    van Vollenhoven RF, Wang L, Merrill JT et al.. “A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.” The New England journal of medicine (2025). PMID: 41092329 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
  129. [129]

    Cervera R, Serrano R, Pons-Estel GJ et al.. “Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.” Annals of the rheumatic diseases (2014). PMID: 24464962 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Special Populations, Pregnancy & Fertility
  130. [130]

    Ramnarain A, Liam C, Milea D et al.. “Predictors of Organ Damage in Systemic Lupus Erythematosus in the Asia Pacific Region: A Systematic Review.” Arthritis care & research (2024). PMID: 38191962 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  131. [131]

    Gao J, Li M, Sun M et al.. “Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.” Lancet (London, England) (2025). PMID: 41240964 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  132. [132]

    Kallas R, Li J, Petri M. “Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study.” Arthritis care & research (2022). PMID: 33342072 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease
  133. [133]

    Wang WH, Lai CC, Huang YF et al.. “Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan.” Arthritis care & research (2022). PMID: 33645012 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  134. [134]

    Wind M, Fierro JJ, Bloemenkamp KWM et al.. “Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis.” The Lancet. Rheumatology (2024). PMID: 39153486 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  135. [135]

    Singh M, Wambua S, Lee SI et al.. “Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.” Lancet (London, England) (2023). PMID: 37997130 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prognosis & Natural History, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  136. [136]

    Nguyen NV, Sandström A, Svenungsson E et al.. “Exposure to hydroxychloroquine in early pregnancy and incidence of pre-eclampsia and pre-term delivery in patients with systemic lupus erythematosus in Sweden: a nationwide population-based cohort study.” The Lancet. Rheumatology (2025). PMID: 40516564 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  137. [137]

    Conrad N, Misra S, Verbakel JY et al.. “Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.” Lancet (London, England) (2023). PMID: 37156255 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors
  138. [138]

    Morand E, Smolen JS, Petri M et al.. “Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.” RMD open (2023). PMID: 37604638 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  139. [139]

    Merrill JT, Saxena A, Aringer M et al.. “Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study.” RMD open (2025). PMID: 40829888 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  140. [140]

    Rees F, Doherty M, Grainge MJ et al.. “The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies.” Rheumatology (Oxford, England) (2017). PMID: 28968809 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  141. [141]

    Pamuk ON, Raza AA, Hasni S. “Neuropsychiatric lupus in late- and early-onset systemic lupus erythematosus patients: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2024). PMID: 37341643 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  142. [142]

    Etchegaray-Morales I, Mendoza-Pinto C, Munguía-Realpozo P et al.. “Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis.” Rheumatology (Oxford, England) (2024). PMID: 38552312 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Flares & Organ-Threatening Disease
  143. [143]

    Forte F, Buonaiuto A, Calcaterra I et al.. “Association of systemic lupus erythematosus with peripheral arterial disease: a meta-analysis of literature studies.” Rheumatology (Oxford, England) (2020). PMID: 32793980 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Prevention, Screening & Surveillance
  144. [144]

    Baker K, Pope J. “Employment and work disability in systemic lupus erythematosus: a systematic review.” Rheumatology (Oxford, England) (2009). PMID: 19153144 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  145. [145]

    Liu X, Jia X, Wang X et al.. “Mental health conditions in patients with systemic lupus erythematosus: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2024). PMID: 38652594 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  146. [146]

    Parodis I, Lindblom J, Palazzo L et al.. “Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial setting.” RMD open (2025). PMID: 41173511 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  147. [147]

    Hanly JG, O'Keeffe AG, Su L et al.. “The frequency and outcome of lupus nephritis: results from an international inception cohort study.” Rheumatology (Oxford, England) (2015). PMID: 26342222 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  148. [148]

    Yazdany J, Pooley N, Langham J et al.. “Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis.” RMD open (2020). PMID: 32900883 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prevention, Screening & Surveillance
  149. [149]

    Tektonidou MG, Andreoli L, Limper M et al.. “EULAR recommendations for the management of antiphospholipid syndrome in adults.” Annals of the rheumatic diseases (2019). PMID: 31092409 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Fertility
  150. [150]

    Gómez-Bañuelos E, Celia AI, Trejo-Zambrano MI et al.. “Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE.” Annals of the rheumatic diseases (2025). PMID: 40350373 ↗

    L5OTHERCited in: Epidemiology, Etiology & Risk Factors
  151. [151]

    Yuan X, Qin X, Takemoto K et al.. “Human hypofunctional NCF1 variants promote pulmonary fibrosis in the bleomycin-induced mouse model and patients with systemic sclerosis via expansion of SPP1+ monocytes-derived macrophages.” Annals of the rheumatic diseases (2025). PMID: 39919902 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors
  152. [152]

    Oliveira C, Temesgen-Oyelakin Y, Naqi M et al.. “A Multiomic Analysis to Identify Drivers of Subclinical Vascular Disease in Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38923259 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors
  153. [153]

    Matsuoka N, Yajima N, Inoue E et al.. “Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study.” RMD open (2025). PMID: 40701623 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
  154. [154]

    Gomez A, Guimarães de Oliveira D, Karakikla-Mitsakou Z et al.. “Associations between social determinants of health and long-term outcomes in systemic lupus erythematosus: a nationwide population-based cohort study in Sweden.” RMD open (2026). PMID: 41494734 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  155. [155]

    Plantinga LC, Yazdany J, Pearce BD et al.. “Fluid Cognition Among Individuals With Systemic Lupus Erythematosus.” Arthritis care & research (2024). PMID: 38528776 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors
  156. [156]

    Kim Y, Koopman JJE, Choi M et al.. “Environmental Risk Factors for Systemic Lupus Erythematosus Through the Lens of Social Determinants of Health.” Arthritis care & research (2025). PMID: 39800912 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  157. [157]

    Cobo-Ibáñez T, Urruticoechea-Arana A, Rúa-Figueroa I et al.. “Hormonal Dependence and Cancer in Systemic Lupus Erythematosus.” Arthritis care & research (2020). PMID: 31529686 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  158. [158]

    Ingegnoli F, Ughi N, Riccieri V et al.. “Distribution of nailfold videocapillaroscopy parameters in systemic lupus erythematosus and their association with disease activity: an international blinded case-control analysis on behalf of the EULAR study group on microcirculation in rheumatic diseases.” RMD open (2025). PMID: 40921627 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  159. [159]

    . “Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.” The Lancet. Rheumatology (2023). PMID: 37927903 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  160. [160]

    Rodziewicz M, Dyball S, Lunt M et al.. “Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.” The Lancet. Rheumatology (2023). PMID: 38251591 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, Complications: Disease-Driven & Treatment-Related
  161. [161]

    Bolla E, Semb AG, Kerola AM et al.. “Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries.” The Lancet. Rheumatology (2024). PMID: 38878780 ↗

    L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  162. [162]

    Raghunath S, Glikmann-Johnston Y, Hanly JG et al.. “Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?” The Lancet. Rheumatology (2022). PMID: 38288924 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  163. [163]

    Eades LE, Hoi AY, Liddle R et al.. “Systemic lupus erythematosus in Aboriginal and Torres Strait Islander peoples in Australia: addressing disparities and barriers to optimising patient care.” The Lancet. Rheumatology (2024). PMID: 38971169 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  164. [164]

    Conrad N, Verbeke G, Molenberghs G et al.. “Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.” Lancet (London, England) (2022). PMID: 36041475 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  165. [165]

    Zöller B, Li X, Sundquist J et al.. “Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden.” Lancet (London, England) (2011). PMID: 22119579 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  166. [166]

    Jin Y, Mailloux CM, Gowan K et al.. “NALP1 in vitiligo-associated multiple autoimmune disease.” The New England journal of medicine (2007). PMID: 17377159 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  167. [167]

    Lee YH, Song GG. “Long-term Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: A Meta-Analysis of Randomized Controlled Trials, Extension Studies, and Real-World Cohorts.” Pharmacology (2026). PMID: 42406697 ↗

    L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
  168. [168]

    Turk MA, Hausman J, Pope JE. “Racial minorities are under-represented in SLE clinical trials: A systematic review and meta-analysis.” Autoimmunity reviews (2026). PMID: 42190855 ↗

    L1TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors
  169. [169]

    Frade S, O'Neill S, Greene D et al.. “Exercise as adjunctive therapy for systemic lupus erythematosus.” The Cochrane database of systematic reviews (2023). PMID: 37073886 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  170. [170]

    Du D, Zeng T, Qin J et al.. “Vaccination coverage of influenza and pneumococcal vaccines in patients with rheumatic diseases: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2026). PMID: 42397204 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
  171. [171]

    Li W, Zhao Y, Shu S et al.. “Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis.” Frontiers in immunology (2026). PMID: 42170175 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
  172. [172]

    Dai X, Ding H, Mao D et al.. “Prevalence of female sexual dysfunction among women with systemic lupus erythematosus: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42158876 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  173. [173]

    Ding HJ, Denniston AK, Rao VK et al.. “Hydroxychloroquine-related retinal toxicity.” Rheumatology (Oxford, England) (2015). PMID: 26428520 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  174. [174]

    Barber MRW, Drenkard C, Falasinnu T et al.. “Global epidemiology of systemic lupus erythematosus.” Nature reviews. Rheumatology (2021). PMID: 34345022 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  175. [175]

    Bultink IEM, Dankers W, de Boer MA et al.. “Fertility, pregnancy and lactation in women with systemic lupus erythematosus.” Nature reviews. Rheumatology (2026). PMID: 41946970 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  176. [176]

    Hyrich KL, Machado PM. “Rheumatic disease and COVID-19: epidemiology and outcomes.” Nature reviews. Rheumatology (2021). PMID: 33339986 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related
  177. [177]

    Mak A, Chan JKY. “Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.” Nature reviews. Rheumatology (2022). PMID: 35393604 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  178. [178]

    Muskardin TLW, Niewold TB. “Type I interferon in rheumatic diseases.” Nature reviews. Rheumatology (2018). PMID: 29559718 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  179. [179]

    Zou Y, Yu R, Yang K et al.. “Baseline neutrophil-to-lymphocyte ratio combined with SLEDAI predicts lupus low disease activity state at 1 year: a cohort study.” Frontiers in immunology (2026). PMID: 42375364 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
  180. [180]

    Riancho-Zarrabeitia L, Vegas-Revenga N, Domínguez-Casas LC et al.. “Leukocyte Telomere Length and Long-Term Clinical Outcomes in Women with Systemic Lupus Erythematosus: A Prospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42355813 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related
  181. [181]

    Fanouriakis A, Kostopoulou M, Cheema K et al.. “2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.” Annals of the rheumatic diseases (2020). PMID: 32220834 ↗

    L1GUIDELINECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  182. [182]

    Pons-Estel BA, Bonfa E, Soriano ER et al.. “First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).” Annals of the rheumatic diseases (2018). PMID: 30045853 ↗

    L1GUIDELINECited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  183. [183]

    Tunnicliffe DJ, Singh-Grewal D, Kim S et al.. “Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines.” Arthritis care & research (2015). PMID: 25778500 ↗

    L5GUIDELINECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  184. [184]

    Kostopoulou M, Mukhtyar CB, Bertsias G et al.. “Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations.” Annals of the rheumatic diseases (2024). PMID: 38777375 ↗

    L2SR_OBSCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  185. [185]

    Morand EF, Werth VP, Wenzel J et al.. “Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.” The Lancet. Rheumatology (2026). PMID: 42107375 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  186. [186]

    Shipa M, Santos LR, Nguyen DX et al.. “Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial.” The Lancet. Rheumatology (2022). PMID: 36756239 ↗

    L1RCTCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  187. [187]

    Wallace DJ, Furie RA, Tanaka Y et al.. “Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.” Lancet (London, England) (2018). PMID: 30043749 ↗

    L1RCTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  188. [188]

    Morand EF, Dall'Era M, Sanchez-Guerrero J et al.. “Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.” Lancet (London, England) (2026). PMID: 42107374 ↗

    L1RCTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  189. [189]

    del Pino-Sedeño T, Trujillo-Martín MM, Ruiz-Irastorza G et al.. “Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review.” Arthritis care & research (2016). PMID: 26238554 ↗

    L2SR_OBSCited in: Clinical Presentation
  190. [190]

    Tamirou F, Arnaud L, Talarico R et al.. “Systemic lupus erythematosus: state of the art on clinical practice guidelines.” RMD open (2018). PMID: 30564454 ↗

    L5GUIDELINECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  191. [191]

    Arends EJ, Zlei M, Tipton CM et al.. “Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.” Rheumatology (Oxford, England) (2024). PMID: 38775637 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  192. [192]

    Silvagni E, Chessa E, Bergossi F et al.. “Relevant domains and outcome measurement instruments in neuropsychiatric systemic lupus erythematosus: a systematic literature review.” Rheumatology (Oxford, England) (2021). PMID: 33788917 ↗

    L2SR_OBSCited in: Clinical Presentation
  193. [193]

    Blomjous BS, Gajadin GRS, Voskuyl AE et al.. “Work participation in patients with systematic lupus erythematosus: a systematic review.” Rheumatology (Oxford, England) (2022). PMID: 34792543 ↗

    L2SR_OBSCited in: Clinical Presentation
  194. [194]

    Parodis I, Gomez A, Tsoi A et al.. “Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.” RMD open (2023). PMID: 37532469 ↗

    L2SR_OBSCited in: Clinical Presentation
  195. [195]

    Wang Y, Xie X, Zhang C et al.. “Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood.” Annals of the rheumatic diseases (2021). PMID: 34462261 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
  196. [196]

    Groot N, de Graeff N, Avcin T et al.. “European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative.” Annals of the rheumatic diseases (2017). PMID: 28630236 ↗

    L1OTHERCited in: Clinical Presentation
  197. [197]

    Nikolopoulos D, Manolakou T, Polissidis A et al.. “Microglia activation in the presence of intact blood-brain barrier and disruption of hippocampal neurogenesis via IL-6 and IL-18 mediate early diffuse neuropsychiatric lupus.” Annals of the rheumatic diseases (2023). PMID: 36898766 ↗

    L5OTHERCited in: Clinical Presentation
  198. [198]

    Fava A, Rao DA, Mohan C et al.. “Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 34783463 ↗

    L3OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  199. [199]

    Liu Y, Carmona-Rivera C, Seto NL et al.. “Role of STING Deficiency in Amelioration of Mouse Models of Lupus and Atherosclerosis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39605244 ↗

    L5OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  200. [200]

    van der Heijden H, Rameh V, Golden E et al.. “Implications of Inflammatory Processes on a Developing Central Nervous System in Childhood-Onset Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37901986 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Special Populations, Pregnancy & Fertility
  201. [201]

    Klein B, Colesa DJ, Gao Y et al.. “Epidermal Interferon-κ Drives Cutaneous Lupus-Like Lesions, Photosensitivity, and Systemic Autoimmunity In Vivo.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40776772 ↗

    L5OTHERCited in: Clinical Presentation
  202. [202]

    Kim AHJ, Strand V, Sen DP et al.. “Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30294950 ↗

    L2OTHERCited in: Clinical Presentation
  203. [203]

    Bianchi M, Kozyrev SV, Notarnicola A et al.. “Unraveling the Genetics of Shared Clinical and Serological Manifestations in Patients With Systemic Inflammatory Autoimmune Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39284741 ↗

    L4OTHERCited in: Clinical Presentation
  204. [204]

    Liang MH, Lew ER, Fraser PA et al.. “Choosing to End African American Health Disparities in Patients With Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38229482 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  205. [205]

    Auth J, Müller F, Völkl S et al.. “CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series.” The Lancet. Rheumatology (2024). PMID: 39542003 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  206. [206]

    Schmidt C, Papo M, Taïeb D et al.. “Severe thrombocytopenia in antiphospholipid syndrome: a retrospective study of 432 patients.” RMD open (2026). PMID: 41956709 ↗

    L2COHORTCited in: Clinical Presentation, Special Populations, Pregnancy & Fertility
  207. [207]

    Fava A, Wagner CA, Guthridge CJ et al.. “Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment.” Arthritis care & research (2025). PMID: 41048053 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  208. [208]

    Johnson SR, Gladman DD, Brunner HI et al.. “Evaluating the Construct of Damage in Systemic Lupus Erythematosus.” Arthritis care & research (2022). PMID: 34962100 ↗

    L5OTHERCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification
  209. [209]

    Touma Z, Cervera R, Brinks R et al.. “Associations Between Classification Criteria Items in Systemic Lupus Erythematosus.” Arthritis care & research (2020). PMID: 31560454 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  210. [210]

    Rice C, Ayyala DN, Shi H et al.. “Sex and Racial Differences in Systemic Lupus Erythematosus Among US Adults in the All of Us Research Program.” Arthritis care & research (2023). PMID: 36705447 ↗

    L4OTHERCited in: Clinical Presentation
  211. [211]

    Chang JC, Varghese SA, Behrens EM et al.. “Improving Outcomes of Pediatric Lupus Care Delivery With Provider Goal-Setting Activities and Multidisciplinary Care Models.” Arthritis care & research (2023). PMID: 37070611 ↗

    L4OTHERCited in: Clinical Presentation
  212. [212]

    Séguin DJ, Peschken CA, Dolovich C et al.. “Polypharmacy and Potentially Inappropriate Medication Use in Older Adults With Systemic Lupus Erythematosus.” Arthritis care & research (2022). PMID: 34369087 ↗

    L4OTHERCited in: Clinical Presentation
  213. [213]

    Arnaud L, Ruiz-Irastorza G, Aranow C et al.. “ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations.” The Lancet. Rheumatology (2025). PMID: 40418946 ↗

    L1REVIEW_NARRATIVECited in: Clinical Presentation
  214. [214]

    Piga M, Chessa E, Morand EF et al.. “Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study.” The Lancet. Rheumatology (2022). PMID: 38293958 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  215. [215]

    Hadjadj J, Wolfers A, Borisov O et al.. “Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study.” The Lancet. Rheumatology (2025). PMID: 40024253 ↗

    L2OTHERCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target
  216. [216]

    Singh JA, Hearld LR, Eisen S et al.. “Patient outcomes from implementing a shared decision-making aid for systemic lupus erythematosus: a prospective implementation study.” The Lancet. Rheumatology (2025). PMID: 40975111 ↗

    L2OTHERCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  217. [217]

    Ruiz-Irastorza G, Crowther M, Branch W et al.. “Antiphospholipid syndrome.” Lancet (London, England) (2010). PMID: 20822807 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Special Populations, Pregnancy & Fertility
  218. [218]

    Trevisani VF, Castro AA, Neves Neto JF et al.. “Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.” The Cochrane database of systematic reviews (2006). PMID: 16625558 ↗

    L1SR_OBSCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  219. [219]

    Li SG, Long T, Yu R et al.. “Adrenal involvement in antiphospholipid syndrome and SLE-spectrum disease: a systematic review and pooled individual-patient analysis.” Frontiers in immunology (2026). PMID: 42317308 ↗

    L1SR_OBSCited in: Clinical Presentation
  220. [220]

    Wang Y, Jiang S, Liu Y et al.. “The association between systemic lupus erythematosus and cognitive impairment or dementia: a meta-analysis.” Frontiers in immunology (2026). PMID: 42311684 ↗

    L2SR_OBSCited in: Clinical Presentation, Prevention, Screening & Surveillance
  221. [221]

    Sivaraj RR, Durrani OM, Denniston AK et al.. “Ocular manifestations of systemic lupus erythematosus.” Rheumatology (Oxford, England) (2007). PMID: 17681981 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  222. [222]

    Mirguet A, Aeschlimann FA, Lemelle I et al.. “Long-term outcomes of childhood-onset systemic lupus erythematosus.” Rheumatology (Oxford, England) (2025). PMID: 39008948 ↗

    L2OTHERCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification
  223. [223]

    Fasano S, Milone A, Nicoletti GF et al.. “Precision medicine in systemic lupus erythematosus.” Nature reviews. Rheumatology (2023). PMID: 37041269 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  224. [224]

    Dörner T, Lipsky PE. “The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus.” Nature reviews. Rheumatology (2024). PMID: 39511302 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  225. [225]

    Pisetsky DS, Eudy AM, Rogers JL et al.. “Pain in systemic lupus erythematosus: emerging insights and paradigms.” Nature reviews. Rheumatology (2025). PMID: 40858989 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  226. [226]

    Wang Y, Jiang S, Liu Y et al.. “Correction: The association between systemic lupus erythematosus and cognitive impairment or dementia: a meta-analysis.” Frontiers in immunology (2026). PMID: 42389521 ↗

    L2SR_OBSCited in: Clinical Presentation
  227. [227]

    Guo Q, Wu D, Zhang X et al.. “Implications of systolic pulmonary artery pressure trajectories in systemic lupus erythematosus-associated pulmonary hypertension: a CSTAR-PAH cohort study.” Frontiers in immunology (2026). PMID: 42344918 ↗

    L3COHORTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
  228. [228]

    Jiang M, Chang Y, Zhang N et al.. “Reassessing the role of antiphospholipid antibodies in placental-mediated adverse pregnancy outcomes in systemic lupus erythematosus: A retrospective cohort study.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42311195 ↗

    L3COHORTCited in: Clinical Presentation
  229. [229]

    Arkin LM, Buhr KA, Ardoin SP et al.. “Progression of skin-limited pediatric-onset discoid lupus erythematosus to diagnosis of systemic lupus erythematosus: results of a multicenter, retrospective cohort study.” Journal of the American Academy of Dermatology (2026). PMID: 42297301 ↗

    L3COHORTCited in: Clinical Presentation, Special Populations, Pregnancy & Fertility
  230. [230]

    Tayer-Shifman OE, Su J, Bingham K et al.. “Intraindividual cognitive function course over time in patients with systemic lupus erythematosus.” RMD open (2025). PMID: 41436139 ↗

    L2OTHERCited in: Clinical Presentation
  231. [231]

    Cha S, Ahn GY, Kim K et al.. “Unveiling the clinical and genetic impact of neuropsychiatric involvement in systemic lupus erythematosus.” RMD open (2025). PMID: 41062154 ↗

    L2OTHERCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target
  232. [232]

    Mönkemöller K, Weber LT, Häusler M et al.. “Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus.” EULAR rheumatology open (2025). PMID: 42367668 ↗

    L1GUIDELINECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  233. [233]

    Sammaritano LR, Askanase A, Bermas BL et al.. “2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.” Arthritis care & research (2025). PMID: 41182321 ↗

    L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Fertility
  234. [234]

    Aranow C, Allaart CF, Amoura Z et al.. “Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.” Annals of the rheumatic diseases (2024). PMID: 39159997 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, History and Evolution of Treatment, Prognosis & Natural History
  235. [235]

    Morand E, Pike M, Merrill JT et al.. “Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36369798 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  236. [236]

    Manzi S, Bruce IN, Morand EF et al.. “Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41466456 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  237. [237]

    Merrill JT, Tanaka Y, D'Cruz D et al.. “Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38923871 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  238. [238]

    Merrill JT, Guthridge J, Smith M et al.. “Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37459248 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  239. [239]

    Wang W, He S, Zhang W et al.. “BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.” Annals of the rheumatic diseases (2024). PMID: 38777376 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  240. [240]

    Chakravarty EF, Utset T, Kamen DL et al.. “Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.” The Lancet. Rheumatology (2024). PMID: 38301682 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  241. [241]

    Strand V, Kalunian KC, Lee KW et al.. “Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.” The Lancet. Rheumatology (2025). PMID: 40324450 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  242. [242]

    Parodis I, Lindblom J, Levy RA et al.. “Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.” The Lancet. Rheumatology (2024). PMID: 39208825 ↗

    L2RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  243. [243]

    Askanase AD, D'Cruz D, Kalunian K et al.. “Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.” The Lancet. Rheumatology (2024). PMID: 39586304 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  244. [244]

    Rovin BH, Teng YKO, Ginzler EM et al.. “Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.” Lancet (London, England) (2021). PMID: 33971155 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
  245. [245]

    Navarra SV, Guzmán RM, Gallacher AE et al.. “Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.” Lancet (London, England) (2011). PMID: 21296403 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prognosis & Natural History
  246. [246]

    Petri M, Bruce IN, Dörner T et al.. “Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).” Lancet (London, England) (2023). PMID: 36848919 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  247. [247]

    Clowse MEB, Isenberg DA, Merrill JT et al.. “Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) (2026). PMID: 42214397 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  248. [248]

    Morand EF, Vital EM, Petri M et al.. “Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).” Lancet (London, England) (2023). PMID: 36848918 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  249. [249]

    Furie RA, van Vollenhoven RF, Kalunian K et al.. “Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.” The New England journal of medicine (2022). PMID: 36069871 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  250. [250]

    Farge D, Biard L, Weil B et al.. “Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study.” The Lancet. Rheumatology (2024). PMID: 39706212 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  251. [251]

    Furie RA, Bruce IN, Dörner T et al.. “Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.” Rheumatology (Oxford, England) (2021). PMID: 33956056 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  252. [252]

    Golder V, Kandane-Rathnayake R, Huq M et al.. “Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.” The Lancet. Rheumatology (2019). PMID: 38229337 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease
  253. [253]

    Tanaka Y, Kumanogoh A, Atsumi T et al.. “Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus.” RMD open (2024). PMID: 39289029 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  254. [254]

    Parodis I, Lindblom J, Palazzo L et al.. “Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.” RMD open (2025). PMID: 40274305 ↗

    L2RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prognosis & Natural History
  255. [255]

    Benjamin S, Vi L, Chatterjee D et al.. “Maternal autoantibodies to the sodium potassium pump α1 subunit AT1A1 and fetal autoimmune congenital heart block: a case-control study.” The Lancet. Rheumatology (2025). PMID: 40412415 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  256. [256]

    Wang H, Li T, Sun F et al.. “Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.” RMD open (2022). PMID: 36288823 ↗

    L4TRIAL_NONRANDOMCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  257. [257]

    Grayson PC, Eddy S, Taroni JN et al.. “Metabolic pathways and immunometabolism in rare kidney diseases.” Annals of the rheumatic diseases (2018). PMID: 29724730 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  258. [258]

    Evans LS, Lewis KE, DeMonte D et al.. “Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36705554 ↗

    L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  259. [259]

    Tarter L, Bermas BL. “Expert Perspective on a Clinical Challenge: Lupus and Pregnancy.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37975160 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  260. [260]

    Yokogawa M, Takaishi M, Nakajima K et al.. “Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24574230 ↗

    L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  261. [261]

    Ostendorf L, Burns M, Durek P et al.. “Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.” The New England journal of medicine (2020). PMID: 32937047 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  262. [262]

    Jacobson R, Goldman D, Fava A et al.. “Hydroxychloroquine Improves Low Complement Levels.” Arthritis care & research (2024). PMID: 38831658 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  263. [263]

    Katz P, Dall'Era M, Plantinga L et al.. “Measuring Frailty in Systemic Lupus Erythematosus.” Arthritis care & research (2025). PMID: 39648405 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  264. [264]

    Urowitz MB, Aranow C, Asukai Y et al.. “Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.” Arthritis care & research (2022). PMID: 35439360 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History, Prevention, Screening & Surveillance
  265. [265]

    Brunner HI, Cody EM, Devarajan P et al.. “The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis.” Arthritis care & research (2026). PMID: 41144892 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  266. [266]

    AlE'ed A, Vega-Fernandez P, Muscal E et al.. “Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood.” Arthritis care & research (2017). PMID: 27992660 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  267. [267]

    D'Cruz DP, Khamashta MA, Hughes GR. “Systemic lupus erythematosus.” Lancet (London, England) (2007). PMID: 17307106 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  268. [268]

    Beigneux AP, Miyashita K, Ploug M et al.. “Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.” The New England journal of medicine (2017). PMID: 28402248 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  269. [269]

    Martinez-Martinez MU, Tejada-Llacsa PJ, Prokop LJ et al.. “Efficacy and safety of belimumab and anifrolumab in systemic lupus erythematosus: A systematic review and network meta-analysis.” Seminars in arthritis and rheumatism (2026). PMID: 42308962 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prognosis & Natural History
  270. [270]

    Muñoz-Urbano M, Sangle S, D'Cruz DP. “Lupus enteritis: a narrative review.” Rheumatology (Oxford, England) (2024). PMID: 38216993 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History
  271. [271]

    Arnold J, Dass S, Twigg S et al.. “Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.” Rheumatology (Oxford, England) (2022). PMID: 35266512 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Prognosis & Natural History
  272. [272]

    Yamaguchi E, Tsuji H, Ogawa A et al.. “The impact of anti-SSA/Ro antibodies on pregnancy outcomes in patients with systemic lupus erythematosus.” Rheumatology (Oxford, England) (2026). PMID: 41838414 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  273. [273]

    Gaubitz M. “Epidemiology of connective tissue disorders.” Rheumatology (Oxford, England) (2006). PMID: 16987829 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  274. [274]

    Miyazaki Y, Funada M, Nakayamada S et al.. “Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.” Rheumatology (Oxford, England) (2024). PMID: 37934129 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease
  275. [275]

    Fillatreau S, Manfroi B, Dörner T. “Toll-like receptor signalling in B cells during systemic lupus erythematosus.” Nature reviews. Rheumatology (2020). PMID: 33339987 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  276. [276]

    Pisetsky DS, Lipsky PE. “New insights into the role of antinuclear antibodies in systemic lupus erythematosus.” Nature reviews. Rheumatology (2020). PMID: 32884126 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  277. [277]

    Morel L. “Immunometabolism in systemic lupus erythematosus.” Nature reviews. Rheumatology (2017). PMID: 28360423 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  278. [278]

    Pozsgay J, Szekanecz Z, Sármay G. “Antigen-specific immunotherapies in rheumatic diseases.” Nature reviews. Rheumatology (2017). PMID: 28701761 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  279. [279]

    Pisetsky DS. “Anti-DNA antibodies--quintessential biomarkers of SLE.” Nature reviews. Rheumatology (2015). PMID: 26581343 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  280. [280]

    Noble PW, Bernatsky S, Clarke AE et al.. “DNA-damaging autoantibodies and cancer: the lupus butterfly theory.” Nature reviews. Rheumatology (2016). PMID: 27009542 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  281. [281]

    Shafau AL, Suhrawardy A, Alazawi H et al.. “Impact of Systemic Lupus Erythematosus on Short-Term and Long-Term Outcomes in Total Knee Arthroplasty: A National Database Propensity-Matched Cohort Study.” Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026). PMID: 42274404 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History, Special Populations, Pregnancy & Fertility
  282. [282]

    Andreoli L, Gerardi MC, Gerosa M et al.. “Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.” RMD open (2024). PMID: 38663885 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prognosis & Natural History, Special Populations, Pregnancy & Fertility
  283. [283]

    Calvo-Río V, Secada-Gómez C, Martín-Gutiérrez A et al.. “Anifrolumab in systemic lupus erythematosus: real-world evidence from a Spanish multicentre cohort of 206 patients and literature review.” RMD open (2026). PMID: 41856562 ↗

    L2REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, History and Evolution of Treatment
  284. [284]

    Akbaba TH, Donmez-Demir B, Colpak AI et al.. “Serum immunoreactivity to neurofilament-medium shows high sensitivity and specificity in patients with Behçet disease.” RMD open (2025). PMID: 40447321 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  285. [285]

    de Melo MMF, Amadei LP, Neto JMC et al.. “Leprosy masquerading as systemic lupus erythematosus: a case report and systematic review of the literature.” Advances in rheumatology (London, England) (2026). PMID: 42321940 ↗

    L4SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  286. [286]

    Vincenti L, Sormani J, Belot A et al.. “Anifrolumab, a potential treatment for ADA2 deficiency.” RMD open (2026). PMID: 42409574 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  287. [287]

    Tian M, Zhang Y, Zhang D et al.. “Modified treatment protocol for pediatric systemic lupus erythematosus-associated hemophagocytic lymphohistiocytosis with central nervous system involvement: a case report.” Frontiers in immunology (2026). PMID: 42396464 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  288. [288]

    Ries AG, Samalik J, Nocton JJ et al.. “Crohn Disease Presenting as Vaginal Discharge in a Patient With Systemic Lupus Erythematosus.” Pediatrics (2026). PMID: 42303253 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  289. [289]

    Duan J, Han L, Zhao W et al.. “Case Report: successful non-surgical management of massive isolated tricuspid Libman-Sacks endocarditis in a pregnant patient with SLE and secondary APS.” Frontiers in immunology (2026). PMID: 42292460 ↗

    L4CASE_REPORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  290. [290]

    Chen WC, Chen YM, Chen IC et al.. “Predominant HLA class I associations with lupus nephritis susceptibility, histology class and reduced renal function in patients with systemic lupus erythematosus: a retrospective case-control study.” Rheumatology international (2026). PMID: 42384312 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  291. [291]

    Dziedzic R, Zaręba L, Siwiec-Koźlik A et al.. “Clinical and laboratory differences in characteristics of patients with early-onset and late-onset systemic lupus erythematosus: a single-center retrospective study.” Reumatologia (2026). PMID: 42306293 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  292. [292]

    Vestin H, Oparina N, Eloranta ML et al.. “Methylation and polygenic risk scores capture different features of systemic lupus erythematosus.” Rheumatology (Oxford, England) (2026). PMID: 42434801 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  293. [293]

    Fanouriakis A, Kostopoulou M, Alunno A et al.. “2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.” Annals of the rheumatic diseases (2019). PMID: 30926722 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  294. [294]

    Parodis I, Girard-Guyonvarc'h C, Arnaud L et al.. “EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.” Annals of the rheumatic diseases (2024). PMID: 37433575 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment
  295. [295]

    Sammaritano LR, Askanase A, Bermas BL et al.. “2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 41187097 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Special Populations, Pregnancy & Fertility
  296. [296]

    Park JK, Kim M, Jung JI et al.. “Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial.” The Lancet. Rheumatology (2024). PMID: 38710192 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  297. [297]

    van Vollenhoven RF, Hahn BH, Tsokos GC et al.. “Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.” Lancet (London, England) (2018). PMID: 30249507 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  298. [298]

    Morand EF, Furie R, Tanaka Y et al.. “Trial of Anifrolumab in Active Systemic Lupus Erythematosus.” The New England journal of medicine (2019). PMID: 31851795 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  299. [299]

    Merrill JT, Werth VP, Furie R et al.. “Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.” The New England journal of medicine (2022). PMID: 35294813 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  300. [300]

    Md Yusof MY, Smith EMD, Lythgoe H et al.. “The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.” Rheumatology (Oxford, England) (2026). PMID: 42336388 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
  301. [301]

    Kandane-Rathnayake R, Louthrenoo W, Luo SF et al.. “Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study.” Arthritis care & research (2022). PMID: 34197023 ↗

    L2COHORTCited in: Severity, Disease Activity & Risk Stratification
  302. [302]

    Golder V, Kandane-Rathnayake R, Li N et al.. “Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.” The Lancet. Rheumatology (2024). PMID: 38876129 ↗

    L2COHORTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  303. [303]

    Baldo F, Erkens RGA, Mizuta M et al.. “Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project.” Rheumatology (Oxford, England) (2025). PMID: 39058514 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Prognosis & Natural History, Prevention, Screening & Surveillance
  304. [304]

    Gwinnutt JM, Wieczorek M, Rodríguez-Carrio J et al.. “Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35654458 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  305. [305]

    Wieczorek M, Gwinnutt JM, Ransay-Colle M et al.. “Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35351808 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  306. [306]

    Kellahan SR, Huang X, Lew D et al.. “Depressed Symptomatology in Systemic Lupus Erythematosus Patients.” Arthritis care & research (2022). PMID: 34890116 ↗

    L2OTHERCited in: Severity, Disease Activity & Risk Stratification
  307. [307]

    Fortin PR, Da Costa D, Neville C et al.. “Challenges of Perceived Self-Management in Lupus.” Arthritis care & research (2022). PMID: 33342087 ↗

    L4OTHERCited in: Severity, Disease Activity & Risk Stratification
  308. [308]

    Holland MJ, Beresford MW, Feldman BM et al.. “Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus.” Arthritis care & research (2018). PMID: 29409150 ↗

    L2OTHERCited in: Severity, Disease Activity & Risk Stratification
  309. [309]

    Furie RA, Morand EF, Bruce IN et al.. “Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.” The Lancet. Rheumatology (2019). PMID: 38229377 ↗

    L1OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  310. [310]

    Furie RA, Dall'Era M, Vital EM et al.. “Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus.” The New England journal of medicine (2026). PMID: 41789864 ↗

    L1OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  311. [311]

    Crosbie D, Black C, McIntyre L et al.. “Dehydroepiandrosterone for systemic lupus erythematosus.” The Cochrane database of systematic reviews (2007). PMID: 17943841 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  312. [312]

    Henderson L, Masson P, Craig JC et al.. “Treatment for lupus nephritis.” The Cochrane database of systematic reviews (2012). PMID: 23235592 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  313. [313]

    Ushijima TS, Teruya H, Abe T et al.. “Stratification of systemic lupus erythematosus with IGHV4-34 in unswitched memory B cells.” Rheumatology (Oxford, England) (2025). PMID: 40650930 ↗

    L4OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease
  314. [314]

    Stockfelt M, Teng YKO, Vital EM. “Opportunities and limitations of B cell depletion approaches in SLE.” Nature reviews. Rheumatology (2025). PMID: 39815102 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  315. [315]

    Lau CS, Mak A. “The socioeconomic burden of SLE.” Nature reviews. Rheumatology (2009). PMID: 19506585 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification
  316. [316]

    Gatto M, Zen M, Iaccarino L et al.. “New therapeutic strategies in systemic lupus erythematosus management.” Nature reviews. Rheumatology (2019). PMID: 30538302 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification
  317. [317]

    Barron ML, Dawson RM, Corbett CF et al.. “Assessing and improving communication strategies among healthcare providers and African American individuals with systemic lupus: a scoping review.” BMC rheumatology (2026). PMID: 42363294 ↗

    L5SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  318. [318]

    Fanouriakis A, Kostopoulou M, Anders HJ et al.. “EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update.” Annals of the rheumatic diseases (2025). PMID: 41107121 ↗

    L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  319. [319]

    Sadun RE, Cooper JC, Belot A et al.. “Development of CARRA/PReS-endorsed consensus Core and Expanded Datasets in childhood-onset systemic lupus erythematosus for international registry-based research.” Annals of the rheumatic diseases (2025). PMID: 39919891 ↗

    L5GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease
  320. [320]

    Fei Y, Zhao L, Wu L et al.. “Evaluation and prediction of relapse risk in stable systemic lupus erythematosus patients after glucocorticoid withdrawal (PRESS): an open-label, multicentre, non-inferiority, randomised controlled study in China.” Annals of the rheumatic diseases (2025). PMID: 39919900 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  321. [321]

    Jourde-Chiche N, Costedoat-Chalumeau N, Baumstarck K et al.. “Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.” Annals of the rheumatic diseases (2022). PMID: 35725295 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  322. [322]

    Sun F, Wang H, Zhang D et al.. “Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.” Annals of the rheumatic diseases (2025). PMID: 41203461 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
  323. [323]

    Connelly K, Kandane-Rathnayake R, Hoi A et al.. “Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36122172 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  324. [324]

    Schletzbaum M, Sweet N, Astor B et al.. “Associations of Postdischarge Follow-Up With Acute Care and Mortality in Lupus: A Medicare Cohort Study.” Arthritis care & research (2023). PMID: 36752354 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  325. [325]

    Rodríguez-Carrio J, Burska A, Conaghan PG et al.. “Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.” RMD open (2023). PMID: 36882218 ↗

    L2SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  326. [326]

    Nikoloudaki M, Barmparis GD, Pitsigavdaki S et al.. “Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study.” RMD open (2026). PMID: 41781160 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  327. [327]

    Mayer SE, Kluberg SA, Spence O et al.. “Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA.” RMD open (2025). PMID: 40780731 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
  328. [328]

    Katechis S, Pitsigavdaki S, Nikoloudaki M et al.. “Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study.” RMD open (2025). PMID: 39762120 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  329. [329]

    Arora S, Katz P, Nika A et al.. “Does Higher Quality of Care in Systemic Lupus Erythematosus Improve Quality of Life?” Arthritis care & research (2023). PMID: 35792677 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  330. [330]

    Brunner HI, Mina R, Pilkington C et al.. “Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus.” Arthritis care & research (2011). PMID: 21618452 ↗

    L5OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  331. [331]

    Feldman CH, Xu C, Costenbader KH. “Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries With Lupus.” Arthritis care & research (2021). PMID: 33949140 ↗

    L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  332. [332]

    Wright TB, Punaro M. “Paediatric systemic lupus erythematosus: insights from translational research.” Rheumatology (Oxford, England) (2017). PMID: 28375454 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  333. [333]

    McElhone K, Abbott J, Hurley M et al.. “Flares in patients with systemic lupus erythematosus.” Rheumatology (Oxford, England) (2021). PMID: 33325488 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  334. [334]

    Arnaud L, Tektonidou MG. “Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors.” Rheumatology (Oxford, England) (2020). PMID: 33280012 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  335. [335]

    Kisaoglu H, Sener S, Demirbas KC et al.. “Severe haematological involvement in children with systemic lupus erythematosus and clinical associations.” Rheumatology (Oxford, England) (2025). PMID: 39093021 ↗

    L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
  336. [336]

    Natoli V, Crow YJ, Hunt DPJ et al.. “Elevated serum interferon-α2 associates with activity and flare risk in juvenile-onset systemic lupus erythematosus.” Rheumatology (Oxford, England) (2025). PMID: 39589907 ↗

    L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  337. [337]

    Mok CC. “Towards new avenues in the management of lupus glomerulonephritis.” Nature reviews. Rheumatology (2016). PMID: 26729459 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  338. [338]

    Brunner HI, Huggins J, Klein-Gitelman MS. “Pediatric SLE--towards a comprehensive management plan.” Nature reviews. Rheumatology (2011). PMID: 21386795 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Fertility
  339. [339]

    Akkara Veetil BM, Bongartz T. “Perioperative care for patients with rheumatic diseases.” Nature reviews. Rheumatology (2011). PMID: 22083219 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  340. [340]

    Zhang L, Chen M, Shen B et al.. “The efficacy and safety of iguratimod treatment in stable systemic lupus erythematosus: a preliminary prospective cohort study.” Frontiers in medicine (2026). PMID: 42305973 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  341. [341]

    Wang C, Bai X, Li J et al.. “Efficacy and safety of telitacicept as an add-on therapy for relapsing lupus nephritis: a retrospective cohort study.” Frontiers in immunology (2026). PMID: 42254007 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  342. [342]

    Kandane-Rathnayake R, Koelmeyer R, Oon S et al.. “Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study.” Arthritis research & therapy (2026). PMID: 42116187 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  343. [343]

    Lemos JR, Lopes AJ, Vigário PDS. “Treatment strategies and clinical outcomes in shrinking lung syndrome in systemic lupus erythematosus: An updated systematic review.” Lupus (2026). PMID: 42301754 ↗

    L4SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Prognosis & Natural History
  344. [344]

    Miyake H, Onishi A, Tsuji H et al.. “Risk factors and the effect of belimumab on flares during glucocorticoid tapering in systemic lupus erythematosus: A multicentre ANSWER-SLE cohort study.” Modern rheumatology (2026). PMID: 42360362 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  345. [345]

    King M, Martinez A, Abbruzzese S et al.. “Pulmonary Hypertension in Systemic Lupus Erythematosus Among Black and Hispanic Patients: An Observational Cohort Study.” Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2026). PMID: 42358118 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  346. [346]

    Baker T, Sharifian H, Newcombe PJ et al.. “Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.” Annals of the rheumatic diseases (2024). PMID: 38569851 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  347. [347]

    Brunner HI, Abud-Mendoza C, Viola DO et al.. “Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.” Annals of the rheumatic diseases (2020). PMID: 32699034 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  348. [348]

    Aranow C, Atish-Fregoso Y, Lesser M et al.. “Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial.” Annals of the rheumatic diseases (2020). PMID: 33144299 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  349. [349]

    Winkler A, Sun W, De S et al.. “The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34423919 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  350. [350]

    Peng J, Dönnes P, Ardoin SP et al.. “Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37786302 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  351. [351]

    Casey KA, Smith MA, Sinibaldi D et al.. “Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 32909675 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  352. [352]

    Jesus D, Henriques C, Matos A et al.. “Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life.” Arthritis care & research (2024). PMID: 38258369 ↗

    L3RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  353. [353]

    Fortin PR, Neville C, Julien AS et al.. “Measuring the Impact of MyLupusGuide in Canada: Results of a Randomized Controlled Study.” Arthritis care & research (2022). PMID: 35225436 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  354. [354]

    Li LC, Feehan LM, Xie H et al.. “Efficacy of a Physical Activity Counseling Program With Use of a Wearable Tracker in People With Inflammatory Arthritis: A Randomized Controlled Trial.” Arthritis care & research (2020). PMID: 32248626 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  355. [355]

    Sciascia S, Cuadrado MJ, Sanna G et al.. “Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort.” Arthritis care & research (2014). PMID: 24964745 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  356. [356]

    Mok CC, Wong CK, To CH et al.. “Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial.” Arthritis care & research (2011). PMID: 21309005 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  357. [357]

    Dall'Era M, Stone D, Levesque V et al.. “Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.” Arthritis care & research (2010). PMID: 21080348 ↗

    L3RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  358. [358]

    Vital EM, Merrill JT, Morand EF et al.. “Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.” Annals of the rheumatic diseases (2022). PMID: 35338035 ↗

    L3TRIAL_NONRANDOMCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring
  359. [359]

    Yin X, Kim K, Suetsugu H et al.. “Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus.” Annals of the rheumatic diseases (2020). PMID: 33272962 ↗

    L3SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  360. [360]

    Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J et al.. “Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review.” Arthritis care & research (2013). PMID: 23609987 ↗

    L2SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  361. [361]

    Lee JE, Mendel A, Malhamé I et al.. “An educational tool to improve PREeclamPsia knowledge and Aspirin adheRence in lupus prEgnancies: the PREPARE trial.” Rheumatology (Oxford, England) (2025). PMID: 40578323 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  362. [362]

    Zhao MH, Cons Molina F, Aroca G et al.. “Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.” Rheumatology (Oxford, England) (2026). PMID: 41092316 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  363. [363]

    Cho J, Shen L, Huq M et al.. “Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.” The Lancet. Rheumatology (2023). PMID: 38251484 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  364. [364]

    Shen N, Weinmann-Menke J, Malvar A et al.. “Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study.” RMD open (2025). PMID: 40813108 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History
  365. [365]

    Xu B, Ruan P, Wu H et al.. “Physical activity in relation to the risk of systemic lupus erythematosus: a prospective study including 401 745 individuals.” Rheumatology (Oxford, England) (2025). PMID: 40342027 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  366. [366]

    Jung YS, Song YJ, Jang EJ et al.. “Immunosuppressant use and adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective cohort study in Korea.” Rheumatology (Oxford, England) (2026). PMID: 41385297 ↗

    L3COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
  367. [367]

    Fanouriakis A, Kostopoulou M, Andersen J et al.. “EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.” Annals of the rheumatic diseases (2024). PMID: 37827694 ↗

    L1OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  368. [368]

    Materne E, Choi H, Zhou B et al.. “Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37262382 ↗

    L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  369. [369]

    Chin A, Terrett A, Kwon M et al.. “Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review.” Arthritis care & research (2025). PMID: 40256995 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
  370. [370]

    Muangchan C, van Vollenhoven RF, Bernatsky SR et al.. “Treatment Algorithms in Systemic Lupus Erythematosus.” Arthritis care & research (2015). PMID: 25777803 ↗

    L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  371. [371]

    Polachek A, Gladman DD, Su J et al.. “Defining Low Disease Activity in Systemic Lupus Erythematosus.” Arthritis care & research (2017). PMID: 27696791 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  372. [372]

    Sun K, Corneli AL, Dombeck C et al.. “Barriers to Taking Medications for Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers, and Clinic Staff.” Arthritis care & research (2022). PMID: 33662174 ↗

    L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  373. [373]

    Mercadé-Besora N, Guo Y, Du M et al.. “Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID-19 Pandemic.” Arthritis care & research (2024). PMID: 38523562 ↗

    L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  374. [374]

    Babaoğlu H, Li J, Goldman D et al.. “Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.” Arthritis care & research (2020). PMID: 31507071 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  375. [375]

    Tselios K, Gladman DD, Touma Z et al.. “Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.” Arthritis care & research (2019). PMID: 30055090 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  376. [376]

    Parodis I, Emamikia S, Gomez A et al.. “Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials.” The Lancet. Rheumatology (2019). PMID: 38229393 ↗

    L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  377. [377]

    Murphy G, Lisnevskaia L, Isenberg D. “Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment.” Lancet (London, England) (2013). PMID: 23972423 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  378. [378]

    Li R, Li X, Zhu X et al.. “Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study.” Journal of autoimmunity (2026). PMID: 42214214 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  379. [379]

    Lin CY, Chien JW, Lin KH et al.. “Regulatory B cell expansion and type 1 innate lymphoid cell suppression characterise immune modulation in paediatric lupus nephritis.” RMD open (2026). PMID: 42128531 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  380. [380]

    Vital E, Wu C, Kahlenberg JM et al.. “Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.” Annals of the rheumatic diseases (2026). PMID: 42115051 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  381. [381]

    Dornjuntai M, Onchan T, Salung L et al.. “Effect of a mobile application-delivered educational video on interest in and uptake of contraception among patients with systemic lupus erythematosus in Thailand: A randomized controlled trial.” Contraception (2026). PMID: 42103414 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  382. [382]

    Østergaard M, Haavardsholm EA, Nowak M et al.. “Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study.” The Lancet. Rheumatology (2026). PMID: 42081904 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  383. [383]

    Martins E, Chindalore VL, Sheng XR et al.. “Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.” Lupus science & medicine (2026). PMID: 42309556 ↗

    L4TRIAL_NONRANDOMCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  384. [384]

    Chen Q, Zhu Y, Xu Q et al.. “CAR-T cell therapy for autoimmune diseases: current clinical trial landscape and the next wave of development.” Frontiers in immunology (2026). PMID: 42292395 ↗

    L5TRIAL_NONRANDOMCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prognosis & Natural History
  385. [385]

    Esteve-Valverde E, Miro-Mur F, Anunciacion-LLunell A et al.. “Hydroxychloroquine and teratogenic risk in pregnancy in systemic autoimmune diseases: A systematic narrative review.” Autoimmunity reviews (2026). PMID: 42173228 ↗

    L5SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
  386. [386]

    Ospina FE, Echeverri A, Zambrano D et al.. “Distinguishing infections vs flares in patients with systemic lupus erythematosus.” Rheumatology (Oxford, England) (2017). PMID: 27744359 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  387. [387]

    Gomez A, Walhelm T, Loeff FC et al.. “Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting.” Rheumatology (Oxford, England) (2025). PMID: 40037576 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring
  388. [388]

    Pego-Reigosa JM, Isenberg DA. “Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease.” Rheumatology (Oxford, England) (2008). PMID: 18658205 ↗

    L4REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  389. [389]

    Lobbes H, Mahévas M, Alviset S et al.. “Pure red cell aplasia in systemic lupus erythematosus, a nationwide retrospective cohort and review of the literature.” Rheumatology (Oxford, England) (2021). PMID: 33871586 ↗

    L4REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  390. [390]

    Xiong W, Lahita RG. “Pragmatic approaches to therapy for systemic lupus erythematosus.” Nature reviews. Rheumatology (2013). PMID: 24166241 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  391. [391]

    Franklyn K, Hoi A, Nikpour M et al.. “The need to define treatment goals for systemic lupus erythematosus.” Nature reviews. Rheumatology (2014). PMID: 25048762 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  392. [392]

    Robinson GA, Knight A, Tucker LB et al.. “Insights into the pathogenesis of childhood-onset SLE in the past decade.” Nature reviews. Rheumatology (2025). PMID: 41258446 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
  393. [393]

    Davila L, Ranganathan P. “Pharmacogenetics: implications for therapy in rheumatic diseases.” Nature reviews. Rheumatology (2011). PMID: 21826093 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  394. [394]

    Davies K, Dures E, Ng WF. “Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.” Nature reviews. Rheumatology (2021). PMID: 34599320 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  395. [395]

    Wallace DJ, Gudsoorkar VS, Weisman MH et al.. “New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.” Nature reviews. Rheumatology (2012). PMID: 22801982 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
  396. [396]

    Hsieh EWY, Chung JB, Amin A et al.. “Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective.” RMD open (2025). PMID: 41052891 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  397. [397]

    Trefond L, Mathian A, Boussouar S et al.. “Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection.” RMD open (2026). PMID: 41825925 ↗

    L3OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  398. [398]

    Pope JE. “Management of Fatigue in Rheumatoid Arthritis.” RMD open (2020). PMID: 32385141 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  399. [399]

    Parodis I, Fanouriakis A, Bortoluzzi A et al.. “Practical insights for the clinical implementation of the EULAR recommendations for patients with systemic lupus erythematosus.” RMD open (2025). PMID: 41475837 ↗

    L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  400. [400]

    Humrich JY, Cacoub P, Rosenzwajg M et al.. “Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.” Annals of the rheumatic diseases (2022). PMID: 35973803 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  401. [401]

    Akiyama S, Hamdeh S, Micic D et al.. “Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.” Annals of the rheumatic diseases (2020). PMID: 33051220 ↗

    L1SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  402. [402]

    Zhang F, Zheng J, Li Y et al.. “Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.” RMD open (2022). PMID: 35428697 ↗

    L4RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring, Complications: Disease-Driven & Treatment-Related
  403. [403]

    Meissner Y, Fischer-Betz R, Andreoli L et al.. “EULAR recommendations for a core data set for pregnancy registries in rheumatology.” Annals of the rheumatic diseases (2020). PMID: 33055080 ↗

    L5OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  404. [404]

    van Vollenhoven RF, Kalunian KC, Dörner T et al.. “Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.” Annals of the rheumatic diseases (2022). PMID: 35798534 ↗

    L1OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  405. [405]

    Jorge A, Ung C, Young LH et al.. “Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.” Nature reviews. Rheumatology (2018). PMID: 30401979 ↗

    L5REVIEW_NARRATIVECited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  406. [406]

    Tanaka Y, Bae SC, Bass D et al.. “Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.” RMD open (2021). PMID: 34215703 ↗

    L4OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  407. [407]

    Temiz A, Noversa de Sousa R, Schoen J et al.. “Real-world longitudinal assessment of anifrolumab in patients with systemic lupus erythematosus: clinical outcomes, safety and modulation of cytokines and neutrophil activity.” RMD open (2026). PMID: 42373105 ↗

    L4OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  408. [408]

    de Carvalho JF, de Oliveira Andrade S, Martinez ATA et al.. “Safety of Accelerated Rituximab Infusion in Rheumatic Diseases: A Systematic Review.” Rheumatology and therapy (2025). PMID: 40517360 ↗

    L2SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  409. [409]

    Tani C, Cardelli C, Zen M et al.. “Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study.” The Journal of rheumatology (2024). PMID: 38950957 ↗

    L4OTHERCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  410. [410]

    Antoniou KM, Distler O, Gheorghiu AM et al.. “ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG).” Annals of the rheumatic diseases (2025). PMID: 40912974 ↗

    L1GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
  411. [411]

    Md Yusof MY, Arnold J, Saleem B et al.. “Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.” The Lancet. Rheumatology (2023). PMID: 36712951 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  412. [412]

    Drosos GC, Vedder D, Houben E et al.. “EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.” Annals of the rheumatic diseases (2022). PMID: 35110331 ↗

    L1OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  413. [413]

    Tang X, Peng Y, Jiang Z et al.. “Efferocytosis and Its Role in Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40452369 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  414. [414]

    Bhargava R, Upadhyay R, Zhao C et al.. “Aberrant Glycosylation of IgG in Children With Active Lupus Nephritis Alters Podocyte Metabolism and Causes Podocyte Injury.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40297959 ↗

    L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  415. [415]

    Arora S, Rovin BH. “Expert Perspective: An Approach to Refractory Lupus Nephritis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35166048 ↗

    L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  416. [416]

    Cerdó T, Woodridge L, Corrales S et al.. “Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41801022 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  417. [417]

    Clowse MEB, Rajendran A, Eudy A et al.. “Pregnancy Outcomes in Patients With Interstitial Lung Disease.” Arthritis care & research (2023). PMID: 34748275 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Special Populations, Pregnancy & Fertility
  418. [418]

    Cheung CK, Yap DYH, Lee KL et al.. “Reduction in Renal Relapse and Preservation of Long-Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis.” Arthritis care & research (2025). PMID: 40685846 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  419. [419]

    Simard JF, Liu EF, Chakravarty E et al.. “Pregnancy Outcomes in a Diverse US Lupus Cohort.” Arthritis care & research (2024). PMID: 38221659 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  420. [420]

    Hagen M, Müller F, Wirsching A et al.. “Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.” The Lancet. Rheumatology (2025). PMID: 40318690 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  421. [421]

    Robinson GA, Peng J, Dönnes P et al.. “Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach.” The Lancet. Rheumatology (2020). PMID: 32818204 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  422. [422]

    Bosch X, Guilabert A, Font J. “Antineutrophil cytoplasmic antibodies.” Lancet (London, England) (2006). PMID: 16876669 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  423. [423]

    Wu L, Guan Z, Zhang X et al.. “Bifidobacterium ameliorates lupus nephritis and modulates aberrant differentiation of lymphocyte subsets.” Rheumatology (Oxford, England) (2025). PMID: 40411762 ↗

    L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  424. [424]

    Renaudineau Y, Treiner E, Herin F et al.. “Interferon-γ release assay as an emergent powerful biomarker in systemic lupus erythematosus.” Rheumatology (Oxford, England) (2025). PMID: 40440161 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  425. [425]

    Henning A, Schrezenmeier E, Dörner T. “Current perspectives on biomarkers to safely guide reduction and withdrawal of immunosuppressants in lupus nephritis.” Rheumatology (Oxford, England) (2026). PMID: 41693011 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  426. [426]

    Perenyei M, Jayne DR, Floßmann O. “Gusperimus: immunological mechanism and clinical applications.” Rheumatology (Oxford, England) (2014). PMID: 24501242 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  427. [427]

    Chen Y, Shi N, Lei X et al.. “The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis.” Rheumatology (Oxford, England) (2025). PMID: 38145455 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  428. [428]

    Davidson A. “What is damaging the kidney in lupus nephritis?” Nature reviews. Rheumatology (2015). PMID: 26581344 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  429. [429]

    Maria NI, Davidson A. “Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy.” Nature reviews. Rheumatology (2020). PMID: 32203285 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  430. [430]

    Shen N, Liang D, Tang Y et al.. “MicroRNAs--novel regulators of systemic lupus erythematosus pathogenesis.” Nature reviews. Rheumatology (2012). PMID: 23070646 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  431. [431]

    Murphy G, Isenberg DA. “New therapies for systemic lupus erythematosus - past imperfect, future tense.” Nature reviews. Rheumatology (2019). PMID: 31165780 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  432. [432]

    Davidson A, Aranow C. “Lupus nephritis: lessons from murine models.” Nature reviews. Rheumatology (2009). PMID: 19949431 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  433. [433]

    Stanford SM, Bottini N. “PTPN22: the archetypal non-HLA autoimmunity gene.” Nature reviews. Rheumatology (2014). PMID: 25003765 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  434. [434]

    Garantziotis P, Moysidou GS, Kapsala N et al.. “Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus.” RMD open (2025). PMID: 40081913 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  435. [435]

    Manet C, Aim MA, Queyrel V et al.. “Determinants of social participation in patients living with systemic lupus erythematosus: the Psy-LUP multicentre study.” RMD open (2025). PMID: 40562684 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  436. [436]

    Fels E, Goncalves C, Jousse-Joulin S et al.. “Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.” RMD open (2026). PMID: 42128527 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  437. [437]

    Ranjan S, Dubey M, Panda AK. “Association of galectin-3 in systemic lupus erythematosus: A systematic review and meta-analysis.” Lupus (2026). PMID: 42418310 ↗

    L2SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  438. [438]

    Alharbi S, Aljohani R. “Mortality and survival in patients with systemic lupus erythematosus in the Middle East and North Africa: a systematic review and meta-analysis.” Rheumatology international (2026). PMID: 42329420 ↗

    L2SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History
  439. [439]

    Fang Y, Kang X, He A et al.. “Case report and literature review: neuropsychiatric systemic lupus erythematosus presenting as massive intracerebral hemorrhage.” Frontiers in immunology (2026). PMID: 42344911 ↗

    L4CASE_REPORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  440. [440]

    Wang Y, Zhao L, Guo S et al.. “Allogeneic mesenchymal stromal cells ameliorate lupus nephritis by regulating lipid metabolism via ASGR1.” Stem cell research & therapy (2026). PMID: 42432741 ↗

    L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  441. [441]

    Mosca M, Tani C, Aringer M et al.. “European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.” Annals of the rheumatic diseases (2009). PMID: 19892750 ↗

    L1GUIDELINECited in: Complications: Disease-Driven & Treatment-Related
  442. [442]

    He J, Zhang R, Shao M et al.. “Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.” Annals of the rheumatic diseases (2019). PMID: 31537547 ↗

    L1RCTCited in: Complications: Disease-Driven & Treatment-Related
  443. [443]

    Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al.. “Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.” Annals of the rheumatic diseases (2010). PMID: 19103632 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  444. [444]

    Beltai A, Barnetche T, Daien C et al.. “Cardiovascular Morbidity and Mortality in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.” Arthritis care & research (2020). PMID: 30570824 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Prognosis & Natural History, Prevention, Screening & Surveillance
  445. [445]

    Gentry CA, Humphrey MB, Thind SK et al.. “Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study.” The Lancet. Rheumatology (2020). PMID: 32984847 ↗

    L2COHORTCited in: Complications: Disease-Driven & Treatment-Related
  446. [446]

    Pego-Reigosa JM, Nicholson L, Pooley N et al.. “The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis.” Rheumatology (Oxford, England) (2021). PMID: 33099651 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  447. [447]

    Tan SYS, Yee AM, Sim JJL et al.. “COVID-19 vaccination in systemic lupus erythematosus: a systematic review of its effectiveness, immunogenicity, flares and acceptance.” Rheumatology (Oxford, England) (2023). PMID: 36271852 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  448. [448]

    Colmegna I, Valerio V, Amiable N et al.. “COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.” RMD open (2023). PMID: 38030231 ↗

    L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  449. [449]

    Cognard J, Pietrement C, Laurent A et al.. “Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort.” Rheumatology (Oxford, England) (2025). PMID: 40279484 ↗

    L2COHORTCited in: Complications: Disease-Driven & Treatment-Related
  450. [450]

    Kerschbaumer A, Smolen JS, Nash P et al.. “Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.” RMD open (2020). PMID: 33188136 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  451. [451]

    Kyriazi N, Vassilakis KD, Bakiri A et al.. “Antiobesity medications in rheumatology. Quo vadis?” Annals of the rheumatic diseases (2025). PMID: 40946026 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  452. [452]

    Wei S, Yoshida N, Finn G et al.. “Pin1-Targeted Therapy for Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 27159270 ↗

    L5OTHERCited in: Complications: Disease-Driven & Treatment-Related
  453. [453]

    Petri M, Elkhalifa M, Li J et al.. “Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 31532077 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  454. [454]

    Li BM, Hung JH, Yang PC et al.. “Weighing Dose-Related Benefits and Risks of Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41423344 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  455. [455]

    Desmarais J, Rosenbaum JT, Costenbader KH et al.. “American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34697918 ↗

    L1OTHERCited in: Complications: Disease-Driven & Treatment-Related
  456. [456]

    Löfström B, Backlin C, Sundström C et al.. “Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers.” Rheumatology (Oxford, England) (2009). PMID: 19608725 ↗

    L3CASE_CONTROLCited in: Complications: Disease-Driven & Treatment-Related
  457. [457]

    Petri M, Joyce D, Haag K et al.. “Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response.” Arthritis care & research (2023). PMID: 36714913 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  458. [458]

    Rasooly D, Moonesinghe R, Fallon E et al.. “Family History of Arthritis, Osteoporosis, and Carpal Tunnel Syndrome and Risk of These Conditions Among US Adults.” Arthritis care & research (2024). PMID: 39155684 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  459. [459]

    Hollander MC, Sage JM, Greenler AJ et al.. “International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus.” Arthritis care & research (2013). PMID: 23463586 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  460. [460]

    Hiraki LT, Feldman CH, Marty FM et al.. “Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid.” Arthritis care & research (2017). PMID: 28217919 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  461. [461]

    Sheane BJ, Gladman DD, Su J et al.. “Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus.” Arthritis care & research (2017). PMID: 27214378 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  462. [462]

    Rees F, Doherty M, Grainge M et al.. “Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012.” Arthritis care & research (2016). PMID: 26473719 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  463. [463]

    Sun F, Wang HJ, Liu Z et al.. “Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.” The Lancet. Rheumatology (2020). PMID: 38268156 ↗

    L1OTHERCited in: Complications: Disease-Driven & Treatment-Related
  464. [464]

    Saxena A, Guttmann A, Masson M et al.. “Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort.” The Lancet. Rheumatology (2021). PMID: 34075358 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  465. [465]

    Rirash F, Tingey PC, Harding SE et al.. “Calcium channel blockers for primary and secondary Raynaud's phenomenon.” The Cochrane database of systematic reviews (2017). PMID: 29237099 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  466. [466]

    Hoving JL, Lacaille D, Urquhart DM et al.. “Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis.” The Cochrane database of systematic reviews (2014). PMID: 25375291 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  467. [467]

    Hong Y, Ye J, Hua C. “Single-cell transcriptome-wide Mendelian randomization and colocalization reveal cell-specific mechanisms in systemic lupus erythematosus.” Rheumatology (Oxford, England) (2026). PMID: 41233983 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  468. [468]

    Ramirez GA, Efthymiou M, Isenberg DA et al.. “Under crossfire: thromboembolic risk in systemic lupus erythematosus.” Rheumatology (Oxford, England) (2019). PMID: 30380105 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  469. [469]

    Wahl D, Pengo V. “Viewpoint: Provoked thrombosis in antiphospholipid syndrome.” Rheumatology (Oxford, England) (2024). PMID: 38320585 ↗

    L5OTHERCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  470. [470]

    Robinson WH, Younis S, Love ZZ et al.. “Epstein-Barr virus as a potentiator of autoimmune diseases.” Nature reviews. Rheumatology (2024). PMID: 39390260 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  471. [471]

    Silverman GJ, Azzouz DF, Gisch N et al.. “The gut microbiome in systemic lupus erythematosus: lessons from rheumatic fever.” Nature reviews. Rheumatology (2024). PMID: 38321297 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  472. [472]

    Kamphuis S, Silverman ED. “Prevalence and burden of pediatric-onset systemic lupus erythematosus.” Nature reviews. Rheumatology (2010). PMID: 20683438 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  473. [473]

    Goel RR, Kotenko SV, Kaplan MJ. “Interferon lambda in inflammation and autoimmune rheumatic diseases.” Nature reviews. Rheumatology (2021). PMID: 33907323 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  474. [474]

    Bultink IE, Lems WF. “Systemic lupus erythematosus and fractures.” RMD open (2015). PMID: 26557383 ↗

    L5OTHERCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  475. [475]

    Melbouci D, Haidar Ahmad A, Decker P. “Neutrophil extracellular traps (NET): not only antimicrobial but also modulators of innate and adaptive immunities in inflammatory autoimmune diseases.” RMD open (2023). PMID: 37562857 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  476. [476]

    Jiang X, Sparks J, Wallace Z et al.. “Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study.” RMD open (2023). PMID: 36889799 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  477. [477]

    Hara N, Okamoto Y, Katsumata Y. “Continuation of belimumab in patients with systemic lupus erythematosus in a real-world setting: A single-center retrospective cohort study.” Lupus (2026). PMID: 42357948 ↗

    L3COHORTCited in: Complications: Disease-Driven & Treatment-Related
  478. [478]

    Wołyniec W, Szajewski M, Nałęcz D. “Sarcoma in patients with systemic lupus erythematosus. A systematic review.” Reumatologia (2025). PMID: 42306295 ↗

    L5SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  479. [479]

    Liu A, Liu Y, Shi L et al.. “Guillain-Barré syndrome following Escherichia coli meningitis after cupping therapy: a case report.” Frontiers in immunology (2026). PMID: 42254014 ↗

    L4CASE_REPORTCited in: Complications: Disease-Driven & Treatment-Related
  480. [480]

    Yoo S, Montazeri A, Bennett D et al.. “Folate and global health review series, part 4: syntheses on folate and autoimmune diseases and skeletal outcomes.” Journal of global health (2026). PMID: 42396914 ↗

    L2REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  481. [481]

    Granstaff K, Jiang S, Nallagatla S et al.. “Cardiovascular risk goal attainment in the United States rheumatologic population.” American journal of preventive cardiology (2026). PMID: 42395074 ↗

    L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
  482. [482]

    Sammaritano LR, Bermas BL, Chakravarty EE et al.. “2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32090480 ↗

    L1GUIDELINECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  483. [483]

    Goodman SM, Springer BD, Chen AF et al.. “2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis care & research (2022). PMID: 35718887 ↗

    L1GUIDELINECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  484. [484]

    Sammaritano LR, Bermas BL, Chakravarty EE et al.. “2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.” Arthritis care & research (2020). PMID: 32090466 ↗

    L1GUIDELINECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  485. [485]

    Garg S, Unnithan R, Hansen KE et al.. “Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.” Arthritis care & research (2021). PMID: 32004406 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  486. [486]

    Bootsma H, Spronk P, Derksen R et al.. “Prevention of relapses in systemic lupus erythematosus.” Lancet (London, England) (1995). PMID: 7783536 ↗

    L1RCTCited in: History and Evolution of Treatment
  487. [487]

    Wei N, Klippel JH, Huston DP et al.. “Randomised trial of plasma exchange in mild systemic lupus erythematosus.” Lancet (London, England) (1983). PMID: 6129368 ↗

    L1RCTCited in: History and Evolution of Treatment
  488. [488]

    Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L et al.. “A trial of contraceptive methods in women with systemic lupus erythematosus.” The New England journal of medicine (2005). PMID: 16354890 ↗

    L1RCTCited in: History and Evolution of Treatment
  489. [489]

    Petri M, Kim MY, Kalunian KC et al.. “Combined oral contraceptives in women with systemic lupus erythematosus.” The New England journal of medicine (2005). PMID: 16354891 ↗

    L1RCTCited in: History and Evolution of Treatment
  490. [490]

    . “A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.” The New England journal of medicine (1991). PMID: 1984192 ↗

    L1RCTCited in: History and Evolution of Treatment
  491. [491]

    Lewis EJ, Hunsicker LG, Lan SP et al.. “A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.” The New England journal of medicine (1992). PMID: 1569973 ↗

    L1RCTCited in: History and Evolution of Treatment
  492. [492]

    Laskin CA, Bombardier C, Hannah ME et al.. “Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.” The New England journal of medicine (1997). PMID: 9219700 ↗

    L1RCTCited in: History and Evolution of Treatment
  493. [493]

    Dall'Era M, Wofsy D. “Systemic lupus erythematosus clinical trials-an interim analysis.” Nature reviews. Rheumatology (2009). PMID: 19491915 ↗

    L5TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  494. [494]

    Gavin PG, Allman EL, Jayne D et al.. “Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.” RMD open (2025). PMID: 41052889 ↗

    L1RCTCited in: History and Evolution of Treatment
  495. [495]

    Buttgereit F, Tam LS. “Glucocorticoid treatment in patients with inflammatory rheumatic diseases: current practice and open questions.” The Lancet. Rheumatology (2026). PMID: 41936369 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  496. [496]

    Ramirez GA, Holopainen NEA, Gerosa M et al.. “Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study.” Rheumatology (Oxford, England) (2025). PMID: 39047157 ↗

    L3COHORTCited in: History and Evolution of Treatment
  497. [497]

    Shakoor N, Michalska M, Harris CA et al.. “Drug-induced systemic lupus erythematosus associated with etanercept therapy.” Lancet (London, England) (2002). PMID: 11867114 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  498. [498]

    Teng YKO, Bredewold EOW, Rabelink TJ et al.. “An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus.” Rheumatology (Oxford, England) (2018). PMID: 29165607 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  499. [499]

    Isenberg DA, Rahman A. “Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE.” Nature reviews. Rheumatology (2013). PMID: 24342984 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  500. [500]

    Thanou A, Merrill JT. “Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.” Nature reviews. Rheumatology (2013). PMID: 24100460 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  501. [501]

    Wallace DJ. “The evolution of drug discovery in systemic lupus erythematosus.” Nature reviews. Rheumatology (2015). PMID: 26122951 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  502. [502]

    Zhu DY, Castrillon C, Akama-Garren E et al.. “Germinal-centre and extrafollicular B cell pathways in systemic lupus erythematosus.” Nature reviews. Rheumatology (2026). PMID: 41946971 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  503. [503]

    Korotkova M, Jakobsson PJ. “Persisting eicosanoid pathways in rheumatic diseases.” Nature reviews. Rheumatology (2014). PMID: 24514915 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  504. [504]

    Kochi Y, Suzuki A, Yamada R et al.. “Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis.” Nature reviews. Rheumatology (2010). PMID: 20234359 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  505. [505]

    Dias C, Isenberg DA. “Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.” Nature reviews. Rheumatology (2011). PMID: 21637317 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  506. [506]

    Eyre S, Orozco G, Worthington J. “The genetics revolution in rheumatology: large scale genomic arrays and genetic mapping.” Nature reviews. Rheumatology (2017). PMID: 28569263 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  507. [507]

    Xu J, Zhang Y, Huang H et al.. “Global perspectives on lupus nephritis: a review of clinical trials and therapeutic innovations.” Frontiers in immunology (2026). PMID: 42233033 ↗

    L5TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  508. [508]

    Williams JN, Dall'Era M, Lim SS et al.. “Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies.” Arthritis care & research (2022). PMID: 33026693 ↗

    L5OTHERCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
  509. [509]

    Charoenwoodhipong P, Harlow SD, Marder W et al.. “Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program.” Arthritis care & research (2020). PMID: 31074595 ↗

    L2OTHERCited in: History and Evolution of Treatment
  510. [510]

    Sinicato NA, de Oliveira L, Lapa A et al.. “Familial Aggregation of Childhood- and Adulthood-Onset Systemic Lupus Erythematosus.” Arthritis care & research (2020). PMID: 31127864 ↗

    L4OTHERCited in: History and Evolution of Treatment
  511. [511]

    Simard JF, Liu EF, Rector A et al.. “Hydroxychloroquine and Pre-eclampsia in a Diverse Cohort of Women With Systemic Lupus Erythematosus.” Arthritis care & research (2024). PMID: 38926748 ↗

    L2OTHERCited in: History and Evolution of Treatment
  512. [512]

    Baihetiyaer M, Zhu X, Wu JS et al.. “From empirical treatment to precision intervention: a multi-database bibliometric analysis of neuropsychiatric systemic lupus erythematosus (2006-2025).” Frontiers in immunology (2026). PMID: 42317317 ↗

    L5SR_OBSCited in: History and Evolution of Treatment
  513. [513]

    Morand EF, Furie RA, Bruce IN et al.. “Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.” The Lancet. Rheumatology (2022). PMID: 38288923 ↗

    L1OTHERCited in: History and Evolution of Treatment
  514. [514]

    Arbuckle MR, McClain MT, Rubertone MV et al.. “Development of autoantibodies before the clinical onset of systemic lupus erythematosus.” The New England journal of medicine (2003). PMID: 14561795 ↗

    L3OTHERCited in: History and Evolution of Treatment
  515. [515]

    Asanuma Y, Oeser A, Shintani AK et al.. “Premature coronary-artery atherosclerosis in systemic lupus erythematosus.” The New England journal of medicine (2003). PMID: 14681506 ↗

    L3OTHERCited in: History and Evolution of Treatment
  516. [516]

    Khamashta MA, Cuadrado MJ, Mujic F et al.. “The management of thrombosis in the antiphospholipid-antibody syndrome.” The New England journal of medicine (1995). PMID: 7885428 ↗

    L2OTHERCited in: History and Evolution of Treatment
  517. [517]

    Wadström H, Arkema EV, Sjöwall C et al.. “Cervical neoplasia in systemic lupus erythematosus: a nationwide study.” Rheumatology (Oxford, England) (2017). PMID: 28039412 ↗

    L2OTHERCited in: History and Evolution of Treatment
  518. [518]

    Huang LW, Wei JC, Chen DY et al.. “Bidirectional association between systemic lupus erythematosus and macrophage activation syndrome: a nationwide population-based study.” Rheumatology (Oxford, England) (2022). PMID: 34146089 ↗

    L3OTHERCited in: History and Evolution of Treatment
  519. [519]

    Ji L, Gao D, Hao Y et al.. “Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.” Rheumatology (Oxford, England) (2022). PMID: 35412598 ↗

    L2OTHERCited in: History and Evolution of Treatment
  520. [520]

    Chevalier K, Thoreau B, Michel M et al.. “Unravelling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum.” RMD open (2025). PMID: 41130746 ↗

    L2OTHERCited in: History and Evolution of Treatment
  521. [521]

    Li D, Pan X, He Z et al.. “HIF-1α in macrophage polarization: roles in immunometabolism and autoimmune diseases.” Journal of leukocyte biology (2026). PMID: 42311122 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  522. [522]

    Ueno M, Kubo S, Todoroki Y et al.. “Immune regulation and cell metabolism in B cell subsets in patients with systemic lupus erythematosus.” Frontiers in immunology (2026). PMID: 42273699 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  523. [523]

    Yuan M, Xu XS. “Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.” Clinical pharmacology and therapeutics (2026). PMID: 42244451 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  524. [524]

    Zhu TY, Tam LS, Li EK. “Cost-of-illness studies in systemic lupus erythematosus: A systematic review.” Arthritis care & research (2011). PMID: 21557530 ↗

    L2SR_OBSCited in: Prognosis & Natural History
  525. [525]

    Lim LS, Lee SJ, Feldman BM et al.. “Systematic review of the quality of prognosis studies in systemic lupus erythematosus.” Arthritis care & research (2014). PMID: 24643975 ↗

    L2SR_OBSCited in: Prognosis & Natural History
  526. [526]

    Rentsch CT, DeVito NJ, MacKenna B et al.. “Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.” The Lancet. Rheumatology (2020). PMID: 33349815 ↗

    L2COHORTCited in: Prognosis & Natural History, Prevention, Screening & Surveillance
  527. [527]

    Wobma H, Ardoin SP, Bonifant CL et al.. “CAR T cell therapy for children with rheumatic disease: the time is now.” Nature reviews. Rheumatology (2025). PMID: 40603629 ↗

    L5REVIEW_NARRATIVECited in: Prognosis & Natural History
  528. [528]

    Bertsias G, Ioannidis JP, Boletis J et al.. “EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.” Annals of the rheumatic diseases (2007). PMID: 17504841 ↗

    L1GUIDELINECited in: Special Populations, Pregnancy & Fertility
  529. [529]

    Goodman SM, Springer BD, Chen AF et al.. “2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35722708 ↗

    L1GUIDELINECited in: Special Populations, Pregnancy & Fertility
  530. [530]

    Goodman SM, Springer B, Guyatt G et al.. “2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28620948 ↗

    L1GUIDELINECited in: Special Populations, Pregnancy & Fertility
  531. [531]

    Petri M, Landy H, Clowse MEB et al.. “Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.” Annals of the rheumatic diseases (2022). PMID: 36198440 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Fertility
  532. [532]

    Tektonidou MG, Lewandowski LB, Hu J et al.. “Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016.” Annals of the rheumatic diseases (2017). PMID: 28794077 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy & Fertility
  533. [533]

    Brunner HI, Antón J, Calvo-Penadés I et al.. “Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial.” Arthritis care & research (2026). PMID: 41261055 ↗

    L4TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Fertility
  534. [534]

    Nguyen NV, Svenungsson E, Dominicus A et al.. “Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study.” Rheumatology (Oxford, England) (2025). PMID: 38479815 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  535. [535]

    Tektonidou MG, Andreoli L, Limper M et al.. “Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.” RMD open (2019). PMID: 31168416 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy & Fertility
  536. [536]

    Berman A, Kenet G, Lubetsky A et al.. “Hydroxychloroquine and pregnancy outcomes in patients with anti-phospholipid syndrome: a systematic review and meta-analysis.” RMD open (2025). PMID: 40866107 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy & Fertility
  537. [537]

    Lien HJT, Pedersen TT, Jakobsen B et al.. “Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies.” Annals of the rheumatic diseases (2024). PMID: 38049980 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  538. [538]

    Kaneko S, Hatano M, Shimbo A et al.. “Serum Cytokine Profiling Differentiates Underlying Diseases in Cytokine Storm Syndrome.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40776831 ↗

    L3OTHERCited in: Special Populations, Pregnancy & Fertility
  539. [539]

    Abisror N, Nguyen Y, Marozio L et al.. “Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study.” RMD open (2020). PMID: 32848089 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  540. [540]

    Bruera S, Lei X, Pundole X et al.. “Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast Cancer.” Arthritis care & research (2022). PMID: 34558796 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  541. [541]

    Murarasu A, Guettrot-Imbert G, Le Guern V et al.. “Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study.” The Lancet. Rheumatology (2022). PMID: 38261392 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  542. [542]

    Le TPA, Loh EW, Tam KW. “Long-term efficacy and safety of belimumab in children with systemic lupus erythematosus: a meta-analysis of real-world data.” Rheumatology (Oxford, England) (2026). PMID: 42036838 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy & Fertility
  543. [543]

    Alle G, Guettrot-Imbert G, Larosa M et al.. “Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients.” Rheumatology (Oxford, England) (2025). PMID: 38837707 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  544. [544]

    Hickman RA, Gordon C. “Causes and management of infertility in systemic lupus erythematosus.” Rheumatology (Oxford, England) (2011). PMID: 21652585 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  545. [545]

    Saar P, Hermann W, Müller-Ladner U. “Connective tissue diseases and pregnancy.” Rheumatology (Oxford, England) (2006). PMID: 16987830 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  546. [546]

    Lateef A, Petri M. “Management of pregnancy in systemic lupus erythematosus.” Nature reviews. Rheumatology (2012). PMID: 22907290 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  547. [547]

    Hersh A, von Scheven E, Yelin E. “Adult outcomes of childhood-onset rheumatic diseases.” Nature reviews. Rheumatology (2011). PMID: 21487383 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  548. [548]

    Tower C, Crocker I, Chirico D et al.. “SLE and pregnancy: the potential role for regulatory T cells.” Nature reviews. Rheumatology (2010). PMID: 20736925 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  549. [549]

    Fu Y, Feng T, Sun C et al.. “Clinical correlates and predictors of thrombocytopenia in childhood-onset systemic lupus erythematosus: a retrospective cohort study.” Pediatric rheumatology online journal (2026). PMID: 42251347 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  550. [550]

    Ma K, Zhou J, Feng J et al.. “Associations between gestational weight gain and birthweight outcomes for women with systemic lupus erythematosus: based on a single-center retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42121100 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  551. [551]

    Mehta B, Jannat-Khah D, Glaser KK et al.. “Fetal and maternal morbidity in pregnant patients with Lupus: a 10-year US nationwide analysis.” RMD open (2023). PMID: 37185223 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  552. [552]

    Jung YM, Park JK, Oh MJ et al.. “Increased risk of congenital malformations in offspring born to women with systemic lupus erythematosus in South Korea: a nationwide population-based study.” RMD open (2023). PMID: 37270202 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  553. [553]

    Petri MA, Kiani AN, Post W et al.. “Lupus Atherosclerosis Prevention Study (LAPS).” Annals of the rheumatic diseases (2010). PMID: 21177297 ↗

    L1RCTCited in: Prevention, Screening & Surveillance
  554. [554]

    Sims S, Rowsey K, Hemmerich C et al.. “Systematic Review of Inequitable Population Representation in Systemic Lupus Erythematosus Clinical Trials.” Arthritis care & research (2025). PMID: 40438917 ↗

    L1TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance
  555. [555]

    Mehat P, Atiquzzaman M, Esdaile JM et al.. “Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review.” Arthritis care & research (2017). PMID: 28086003 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  556. [556]

    Jiang Y, Rudin RS, Solomon DH. “Clinical Visit Frequencies in Rheumatology: A Systematic Literature Review.” Arthritis care & research (2023). PMID: 36807719 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  557. [557]

    Petrocchi V, Visintini E, De Marchi G et al.. “Patient Experiences of Systemic Lupus Erythematosus: Findings From a Systematic Review, Meta-Summary, and Meta-Synthesis.” Arthritis care & research (2022). PMID: 34133081 ↗

    L5SR_OBSCited in: Prevention, Screening & Surveillance
  558. [558]

    Grimaldi-Bensouda L, Le Guern V, Kone-Paut I et al.. “The risk of systemic lupus erythematosus associated with vaccines: an international case-control study.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24591123 ↗

    L3CASE_CONTROLCited in: Prevention, Screening & Surveillance
  559. [559]

    Ramanujan SA, Cravens EN, Krishfield SM et al.. “Estrogen-Induced hsa-miR-10b-5p Is Elevated in T Cells From Patients With Systemic Lupus Erythematosus and Down-Regulates Serine/Arginine-Rich Splicing Factor 1.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33982889 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  560. [560]

    Lim SS, Nadipelli VR, Bruno M et al.. “Screening for Social Determinants of Health in Patients With Systemic Lupus Erythematosus: A Point-of-Care Feasibility Study.” Arthritis care & research (2025). PMID: 40386910 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  561. [561]

    Zhang Z, Li F, Li Y et al.. “Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial.” Lupus science & medicine (2026). PMID: 42161432 ↗

    L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance
  562. [562]

    Hu Y, Wen M, Wen L et al.. “Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.” Journal of neurology (2026). PMID: 42390536 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  563. [563]

    Linge P, Fortin PR, Lood C et al.. “The non-haemostatic role of platelets in systemic lupus erythematosus.” Nature reviews. Rheumatology (2018). PMID: 29559714 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  564. [564]

    Deane KD, El-Gabalawy H. “Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.” Nature reviews. Rheumatology (2014). PMID: 24514912 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  565. [565]

    You H, Zhao J, Zhang M et al.. “Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus.” RMD open (2023). PMID: 37996129 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  566. [566]

    Wang K, Zhao J, Feng X et al.. “PD-1/PD-L1 governed cross-talk of exhausted CD8+ T and memory B cells in systemic lupus erythematosus.” RMD open (2024). PMID: 38233074 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…